

Alessandro Rambaldi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4186287/publications.pdf>

Version: 2024-02-01

930
papers

48,278
citations

1118

115
h-index

3508

188
g-index

941
all docs

941
docs citations

941
times ranked

33582
citing authors

#	ARTICLE	IF	CITATIONS
1	Generation and validation of a PET radiomics model that predicts survival in diffuse large B cell lymphoma treated with Râ€CHOP14: A SAKK 38/07 trial postâ€hoc analysis. <i>Hematological Oncology</i> , 2022, 40, 12-22.	0.8	13
2	Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study. <i>Blood Advances</i> , 2022, 6, 373-375.	2.5	34
3	Sequential allogeneic transplantation and ruxolitinib maintenance for a synchronous PCM1â€JAK2 positive myeloid sarcoma and acute Bâ€lymphoblastic leukemia. <i>Clinical Case Reports (discontinued)</i> , 2022, 10, e05212.	0.2	7
4	Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 416-422.	1.3	11
5	Second versus first wave of COVID-19 in patients with MPN. <i>Leukemia</i> , 2022, 36, 897-900.	3.3	7
6	Optimization of therapeutic T cell expansion in G-Rex device and applicability to large-scale production for clinical use. <i>Cytotherapy</i> , 2022, 24, 334-343.	0.3	5
7	Human inhalable antibody fragments neutralizing SARS-CoV-2 variants for COVID-19 therapy. <i>Molecular Therapy</i> , 2022, 30, 1979-1993.	3.7	15
8	Effect of prophylactic or pre-emptive use of tyrosine kinase inhibitors post-Allo SCT in bcr-abl positive acute lymphoblastic leukemia: a subanalysis of GITMO ph-positive ALL study. <i>Bone Marrow Transplantation</i> , 2022, 57, 834-836.	1.3	1
9	Diagnostic Workup of Acute Myeloid Leukemia: What Is Really Necessary? An Italian Survey. <i>Frontiers in Oncology</i> , 2022, 12, 828072.	1.3	2
10	Myeloablative conditioning with thiotepa-busulfan-fludarabine does not improve the outcome of patients transplanted with active leukemia: final results of the GITMO prospective trial GANDALF-01. <i>Bone Marrow Transplantation</i> , 2022, 57, 949-958.	1.3	7
11	Narsoplimab, a Mannan-Binding Lectin-Associated Serine Protease-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem-Cell Transplantationâ€Associated Thrombotic Microangiopathy. <i>Journal of Clinical Oncology</i> , 2022, 40, 2447-2457.	0.8	36
12	High interâ€follicular spatial coâ€localization of CD8+FOXP3+ with CD4+CD8+ cells predicts favorable outcome in follicular lymphoma. <i>Hematological Oncology</i> , 2022, 40, 541-553.	0.8	6
13	Treosulfan compared with <scp>reducedâ€intensity</scp> busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Final analysis of a prospective randomized trial. <i>American Journal of Hematology</i> , 2022, 97, 1023-1034.	2.0	17
14	Digital Droplet PCR Is a Reliable Tool to Improve Minimal Residual Disease Stratification in Adult Philadelphia-Negative Acute Lymphoblastic Leukemia. <i>Journal of Molecular Diagnostics</i> , 2022, 24, 893-900.	1.2	7
15	Inhibition of the lectin pathway of complement ameliorates hypocomplementemia and restores serum bactericidal activity in patients with severe COVIDâ€19. <i>Clinical and Translational Medicine</i> , 2022, 12, .	1.7	6
16	A three-gene signature based on <i>MYC</i>, <i>BCL-2</i>, and <i>NFKB1A</i> improves risk stratification in diffuse large B-cell lymphoma. <i>Haematologica</i> , 2021, 106, 2405-2416.	1.7	8
17	Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913. <i>Haematologica</i> , 2021, 106, 1559-1568.	1.7	49
18	The outcome of two or more HLA loci mismatched unrelated donor hematopoietic cell transplantation for acute leukemia: an ALWP of the EBMT study. <i>Bone Marrow Transplantation</i> , 2021, 56, 20-29.	1.3	1

#	ARTICLE	IF	CITATIONS
19	Upfront stem cell transplantation for newly diagnosed multiple myeloma with del(17p) and t(4;14): a study from the CMWP-EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 210-217.	1.3	7
20	Comparable outcomes of haploidentical transplant with TBF conditioning versus matched unrelated donor with fludarabine/busulfan conditioning for acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2021, 56, 622-634.	1.3	9
21	Splenectomy before allogeneic hematopoietic stem cell transplantation for myelofibrosis: Tumor burden matters!. <i>American Journal of Hematology</i> , 2021, 96, 12-13.	2.0	2
22	Macrophage expression and prognostic significance of the long pentraxin PTX3 in COVID-19. <i>Nature Immunology</i> , 2021, 22, 19-24.	7.0	101
23	Allelic HLA Matching and Pair Origin Are Favorable Prognostic Factors for Unrelated Hematopoietic Stem Cell Transplantation in Neoplastic Hematologic Diseases: An Italian Analysis by the Gruppo Italiano Trapianto di Cellule Staminali e Terapie Cellulari, Italian Bone Marrow Donor Registry, and Associazione Italiana di Immunogenetica e Biologia dei Trapianti. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 106-113.	0.6	4
24	Total body irradiation + fludarabine compared to busulfan + fludarabine as reduced-toxicity conditioning for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 481-491.	1.3	10
25	Convalescent hyperimmune plasma for chemo-immunotherapy induced immunodeficiency in COVID-19 patients with hematological malignancies. <i>Leukemia and Lymphoma</i> , 2021, 62, 1490-1496.	0.6	37
26	CD123 Is Consistently Expressed on NPM1-Mutated AML Cells. <i>Cancers</i> , 2021, 13, 496.	1.7	20
27	High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib. <i>Leukemia</i> , 2021, 35, 485-493.	3.3	70
28	Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2021, 384, 705-716.	13.9	1,129
29	Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19. <i>Blood Cancer Journal</i> , 2021, 11, 21.	2.8	26
30	Immunotherapy of Acute Lymphoblastic Leukemia and Lymphoma With T Cell-Redirected Bispecific Antibodies. <i>Journal of Clinical Oncology</i> , 2021, 39, 444-455.	0.8	18
31	Bergamo and Covid-19: How the Dark Can Turn to Light. <i>Frontiers in Medicine</i> , 2021, 8, 609440.	1.2	15
32	Long-term follow-up of blinatumomab in patients with relapsed/refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukaemia: Final analysis of ALCANTARA study. <i>European Journal of Cancer</i> , 2021, 146, 107-114.	1.3	36
33	Long-term safety and efficacy of givinostat in polycythemia vera: 4-year mean follow up of three phase 1/2 studies and a compassionate use program. <i>Blood Cancer Journal</i> , 2021, 11, 53.	2.8	24
34	Gene expression profile correlates with molecular and clinical features in patients with myelofibrosis. <i>Blood Advances</i> , 2021, 5, 1452-1462.	2.5	8
35	Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV) Tj ETQq1 1 0.784314 rgBT /Overloc	2.2	79
36	Outcomes following second allogeneic haematopoietic cell transplantation in patients with myelofibrosis: a retrospective study of the Chronic Malignancies Working Party of EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 1944-1952.	1.3	7

#	ARTICLE	IF	CITATIONS
37	Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2021, 39, 1223-1233.	0.8	127
38	MRD-Based Therapeutic Decisions in Genetically Defined Subsets of Adolescents and Young Adult Philadelphia-Negative ALL. <i>Cancers</i> , 2021, 13, 2108.	1.7	5
39	Pre-existing immune checkpoints activation predicts relapse after allogeneic stem cell transplantation in lymphoma. <i>Bone Marrow Transplantation</i> , 2021, 56, 2280-2283.	1.3	0
40	Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19. <i>Leukemia</i> , 2021, 35, 2710-2714.	3.3	42
41	Long-term follow-up of recovered MPN patients with COVID-19. <i>Blood Cancer Journal</i> , 2021, 11, 115.	2.8	9
42	Host immune system modulation in Ph+ acute lymphoblastic leukemia patients treated with dasatinib and blinatumomab. <i>Blood</i> , 2021, 138, 2290-2293.	0.6	15
43	Updated results of the placebo-controlled, phase III JAKARTA trial of fedratinib in patients with intermediate- or high-risk myelofibrosis. <i>British Journal of Haematology</i> , 2021, 195, 244-248.	1.2	37
44	Upfront intensive chemo-immunotherapy with autograft in 199 adult mantle cell lymphoma patients: prolonged survival and cure potentiality at long term. <i>Bone Marrow Transplantation</i> , 2021, 56, 2606-2609.	1.3	3
45	Skip pattern approach toward the early access of innovative anticancer drugs. <i>ESMO Open</i> , 2021, 6, 100227.	2.0	1
46	Novel <i>NPM1</i> exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AML. <i>Blood</i> , 2021, 138, 2696-2701.	0.6	30
47	Concurrent diagnosis of acute myeloid leukemia and symptomatic COVID-19 infection: a case report successfully treated with Azacitidine-Venetoclax combination. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2021, 13, e2021057.	0.5	7
48	Increased Plasma Levels of lncRNAs LINC01268, GAS5 and MALAT1 Correlate with Negative Prognostic Factors in Myelofibrosis. <i>Cancers</i> , 2021, 13, 4744.	1.7	9
49	Clinical significance of chromatin-spliceosome acute myeloid leukemia: a report from the Northern Italy Leukemia Group (NILG) randomized trial 02/06. <i>Haematologica</i> , 2021, 106, 2578-2587.	1.7	15
50	COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. <i>Leukemia</i> , 2021, 35, 3444-3454.	3.3	57
51	Lesion Dissemination in Baseline PET/CT (D-MAX) and IPS Score Predict ABVD Treatment Outcome in PET-2 Negative Advanced-Stage Hodgkin Lymphoma Patients Enrolled in the Prospective GITIL/FIL HD0607 Trial. <i>Blood</i> , 2021, 138, 2443-2443.	0.6	3
52	A Phase 2 Study of Pemigatinib (FIGHT-203; INCB054828) in Patients with Myeloid/Lymphoid Neoplasms (MLNs) with Fibroblast Growth Factor Receptor 1 (FGFR1) Rearrangement (MLN <i>FGFR1</i>). <i>Blood</i> , 2021, 138, 385-385.	0.6	22
53	A Phase 1b Study of Blinatumomab Including Subcutaneous Administration in Relapsed / Refractory (R/R) Indolent Non Hodgkin's Lymphoma (NHL). <i>Blood</i> , 2021, 138, 2436-2436.	0.6	5
54	The Interaction between IPSS Score and JAK2 Mutation Identifies Patients at Different Vascular Risk in Primary Myelofibrosis. <i>Blood</i> , 2021, 138, 236-236.	0.6	2

#	ARTICLE	IF	CITATIONS
55	Second <i>Versus</i> First Wave of COVID-19 in Patients with MPN. <i>Blood</i> , 2021, 138, 315-315.	0.6	0
56	Donor-Derived CAR T Cells Engineered with Sleeping Beauty in Pediatric and Adult Patients with Acute Lymphoblastic Leukemia Relapsed Post-HSCT. <i>Blood</i> , 2021, 138, 472-472.	0.6	2
57	OAB-027: Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated results from KarMMa. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S17-S18.	0.2	7
58	Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial. <i>Leukemia</i> , 2020, 34, 914-918.	3.3	46
59	Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial. <i>Lancet Haematology</i> , the, 2020, 7, e28-e39.	2.2	94
60	Impact of bone marrow fibrosis grade in postâ€polycythemia vera and postâ€essential thrombocythemia myelofibrosis: A study of the MYSEC group. <i>American Journal of Hematology</i> , 2020, 95, E1-E3.	2.0	8
61	Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosomeâ€positive Bâ€precursor acute lymphoblastic leukemia. <i>Cancer</i> , 2020, 126, 304-310.	2.0	49
62	Allogeneic Hemopoietic Stem Cell Transplants in Patients with Acute Myeloid Leukemia (AML) Prepared with Busulfan and Fludarabine (BUFLU) or Thiotepa, Busulfan, and Fludarabine (TBF): A Retrospective Study. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 698-703.	2.0	19
63	Characteristics of graftâ€versusâ€host disease occurring after alemtuzumabâ€containing allogeneic stem cell transplants: incidence, organ involvement, risk factors and survival. <i>British Journal of Haematology</i> , 2020, 188, 550-559.	1.2	9
64	Second cancers in MPN: Survival analysis from an international study. <i>American Journal of Hematology</i> , 2020, 95, 295-301.	2.0	34
65	Dasatinibâ€Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults. <i>New England Journal of Medicine</i> , 2020, 383, 1613-1623.	13.9	279
66	A multistate model of survival prediction and event monitoring in prefibrotic myelofibrosis. <i>Blood Cancer Journal</i> , 2020, 10, 100.	2.8	19
67	Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study. <i>Lancet Haematology</i> , the, 2020, 7, e861-e873.	2.2	34
68	The neutrophil to lymphocyte ratio (NLR) and the presence of large nodal mass are independent predictors of early response: A subanalysis of the prospective phase II PETâ€2â€adapted HD0607 trial. <i>Cancer Medicine</i> , 2020, 9, 8735-8746.	1.3	10
69	Updated risk-oriented strategy for acute lymphoblastic leukemia in adult patients 18â€65 years: NILG ALL 10/07. <i>Blood Cancer Journal</i> , 2020, 10, 119.	2.8	29
70	Endothelial injury and thrombotic microangiopathy in COVID-19: Treatment with the lectin-pathway inhibitor narsoplimab. <i>Immunobiology</i> , 2020, 225, 152001.	0.8	120
71	Longâ€term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials. <i>Cancer Medicine</i> , 2020, 9, 6565-6575.	1.3	29
72	Immature Immunoglobulin Gene Rearrangements Are Recurrent in B Precursor Adult Acute Lymphoblastic Leukemia Carrying TP53 Molecular Alterations. <i>Genes</i> , 2020, 11, 960.	1.0	2

#	ARTICLE	IF	CITATIONS
73	Consolidation Radiotherapy Could Be Safely Omitted in Advanced Hodgkin Lymphoma With Large Nodal Mass in Complete Metabolic Response After ABVD: Final Analysis of the Randomized GITIL/FIL HD0607 Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 3905-3913.	0.8	36
74	High Throughput Molecular Characterization of Normal Karyotype Acute Myeloid Leukemia in the Context of the Prospective Trial 02/06 of the Northern Italy Leukemia Group (NILG). <i>Cancers</i> , 2020, 12, 2242.	1.7	5
75	Selective inhibition of Ph-positive ALL cell growth through kinase-dependent and -independent effects by CDK6-specific PROTACs. <i>Blood</i> , 2020, 135, 1560-1573.	0.6	53
76	An agenda for future research projects in polycythemia vera and essential thrombocythemia. <i>Haematologica</i> , 2020, 105, 1999-2003.	1.7	6
77	Impact of detectable measurable residual disease on umbilical cord blood transplantation. <i>American Journal of Hematology</i> , 2020, 95, 1057-1065.	2.0	12
78	Capture-Based Next-Generation Sequencing Improves the Identification of Immunoglobulin/T-Cell Receptor Clonal Markers and Gene Mutations in Adult Acute Lymphoblastic Leukemia Patients Lacking Molecular Probes. <i>Cancers</i> , 2020, 12, 1505.	1.7	11
79	Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2020, 61, 2103-2112.	0.6	55
80	Next-generation sequencing for BCR-ABL1 kinase domain mutations in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position paper. <i>Cancer Medicine</i> , 2020, 9, 2960-2970.	1.3	7
81	Treatment of steroid resistant acute graft versus host disease with an anti-CD26 monoclonal antibody—Beigelomab. <i>Bone Marrow Transplantation</i> , 2020, 55, 1580-1587.	1.3	21
82	COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. <i>Leukemia</i> , 2020, 34, 2354-2363.	3.3	198
83	Early serum ^{TARC} reduction predicts prognosis in advanced-stage ^{Hodgkin} lymphoma patients treated with a ^{PET}-adapted strategy. <i>Hematological Oncology</i> , 2020, 38, 501-508.	0.8	8
84	Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part Phase Ib/II study. <i>Leukemia</i> , 2020, 34, 2234-2237.	3.3	34
85	Rabbit ATG/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus-based recommendations by an international expert panel. <i>Bone Marrow Transplantation</i> , 2020, 55, 1093-1102.	1.3	78
86	Low levels of ^{ADAMTS}13 with high ^{anti-ADAMTS}13 antibodies during remission of immune-mediated thrombotic thrombocytopenic purpura highly predict for disease relapse: A multi-institutional study. <i>American Journal of Hematology</i> , 2020, 95, 953-959.	2.0	14
87	SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model. <i>Blood Advances</i> , 2020, 4, 1082-1092.	2.5	47
88	Blinatumomab consolidation and maintenance therapy in adults with relapsed/refractory B-precursor acute lymphoblastic leukemia. <i>Blood Advances</i> , 2020, 4, 1518-1525.	2.5	11
89	Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study. <i>Blood</i> , 2020, 135, 381-386.	0.6	18
90	Early peripheral clearance of leukemia-associated immunophenotypes in AML: centralized analysis of a randomized trial. <i>Blood Advances</i> , 2020, 4, 301-311.	2.5	8

#	ARTICLE	IF	CITATIONS
91	Sleeping Beautyâ€“engineered CAR T cells achieve antileukemic activity without severe toxicities. <i>Journal of Clinical Investigation</i> , 2020, 130, 6021-6033.	3.9	102
92	Donor-Derived CAR T Cells Engineered with Sleeping Beauty Achieve Anti-Leukemic Activity without Severe Toxicity. <i>Blood</i> , 2020, 136, 34-34.	0.6	0
93	Real-World Effectiveness and Safety of Blinatumomab in Adults with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukaemia in Europe: 3-Year Results in Philadelphia Chromosome-Negative Patients and a Subset of Patients with Late First Relapse. <i>Blood</i> , 2020, 136, 38-39.	0.6	2
94	Hematopoietic stem cell transplantation for adult patients with isolated <i>NPM1</i> mutated acute myeloid leukemia in first remission. <i>American Journal of Hematology</i> , 2019, 94, 231-239.	2.0	15
95	CONSOLIDATION RADIOTHERAPY COULD BE OMITTED IN ADVANCED HODGKIN LYMPHOMA WITH LARGE NODAL MASS IN COMPLETE METABOLIC RESPONSE AFTER ABVD. FINAL ANALYSIS OF THE RANDOMIZED HD0607 TRIAL. <i>Hematological Oncology</i> , 2019, 37, 147-148.	0.8	3
96	Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors: A Registry-Based Study of the Italian Blood and Marrow Transplantation Society (GITMO). <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2388-2397.	2.0	33
97	Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trial. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 1001-1012.	4.6	25
98	A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis. <i>Leukemia</i> , 2019, 33, 2974-2978.	3.3	19
99	MULTI-OMICS LANDSCAPE OF SPLENIC MARGINAL ZONE LYMPHOMA (SMZL) - INTERIM ANALYSIS OF IELSG46 STUDY. <i>Hematological Oncology</i> , 2019, 37, 181-182.	0.8	0
100	Haploidentical Stem Cell Transplantation With Posttransplant Cyclophosphamide Therapy vs Other Donor Transplantations in Adults With Hematologic Cancers. <i>JAMA Oncology</i> , 2019, 5, 1739.	3.4	76
101	BRENTUXIMAB-VEDOTIN AND BENDAMUSTINE IS A FEASIBLE AND EFFECTIVE DRUG COMBINATION AS FIRST-LINE TREATMENT OF HODGKIN LYMPHOMA IN THE ELDERLY (HALO TRIAL). <i>Hematological Oncology</i> , 2019, 37, 292-293.	0.8	2
102	Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea. <i>Blood</i> , 2019, 134, 1498-1509.	0.6	123
103	Molecular Detection of Minimal Residual Disease before Allogeneic Stem Cell Transplantation Predicts a High Incidence of Early Relapse in Adult Patients with <i>NPM1</i> Positive Acute Myeloid Leukemia. <i>Cancers</i> , 2019, 11, 1455.	1.7	20
104	Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients. <i>Cancer Medicine</i> , 2019, 8, 4089-4092.	1.3	16
105	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISM): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 781-794.	5.1	254
106	Blinatumomab for Acute Lymphoblastic Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1498-1504.	2.0	49
107	Infection control in patients treated for chronic lymphocytic leukemia with ibrutinib or idelalisib: recommendations from Italian society of hematology. <i>Leukemia Research</i> , 2019, 81, 88-94.	0.4	11
108	Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-III trial. <i>Haematologica</i> , 2019, 104, 2241-2248.	1.7	13

#	ARTICLE	IF	CITATIONS
109	Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation. <i>Nature Medicine</i> , 2019, 25, 603-611.	15.2	253
110	Influence of Donor and Recipient Gender on Telomere Maintenance after Umbilical Cord Blood Cell Transplantation: A Study by the Gruppo Italiano Trapianto Di Midollo Osseo. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1387-1394.	2.0	2
111	Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia. <i>Hematology</i> , 2019, 24, 337-348.	0.7	48
112	Randomized trial comparing standard vs sequential high-dose chemotherapy for inducing early CR in adult AML. <i>Blood Advances</i> , 2019, 3, 1103-1117.	2.5	23
113	Eltrombopag for immune thrombocytopenia secondary to chronic lymphoproliferative disorders: a phase 2 multicenter study. <i>Blood</i> , 2019, 134, 1708-1711.	0.6	16
114	S113 GENETICS AND MODELING OF HUMAN ACUTE ERYTHROID LEUKEMIA. <i>HemaSphere</i> , 2019, 3, 8-9.	1.2	0
115	INTEGRATION BETWEEN METABOLIC TUMOUR VOLUME AND METABOLIC HETEROGENEITY PREDICTS OUTCOME OF DLBCL LYMPHOMA PATIENTS IN THE SAKK 38/07 STUDY COHORT. <i>Hematological Oncology</i> , 2019, 37, 77-78.	0.8	0
116	AUTOLOGOUS STEM CELL TRANSPLANTATION AS PART OF FIRST-LINE THERAPY IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA: A MULTICENTER GELTAMO/FIL STUDY. <i>Hematological Oncology</i> , 2019, 37, 98-99.	0.8	1
117	INTEGRATING TUMOR- AND MICROENVIRONMENT-REFLECTING GENES IN A UNIQUE AND ROUTINE-APPLICABLE ASSAY FOR ACCURATE RISK PREDICTION IN DLBCL. <i>Hematological Oncology</i> , 2019, 37, 139-140.	0.8	0
118	Newly-Diagnosed, Non-Transplant Eligible Multiple Myeloma Patients: Determinants of Choice of First-Line Treatment in a Single-Center. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e235-e236.	0.2	0
119	S1617 A DASATINIB+BLINATUMOMAB COMBINATION FOR THE FRONT-LINE TREATMENT OF ADULT PH+ ALL PATIENTS. PRELIMINARY RESULTS OF THE GIMEMA LAL2116 +ALBA TRIAL; ON BEHALF OF GIMEMA ACUTE LEUKEMIA WORKING PARTY. <i>HemaSphere</i> , 2019, 3, 746.	1.2	7
120	Nanopore Targeted Sequencing for Rapid Gene Mutations Detection in Acute Myeloid Leukemia. <i>Genes</i> , 2019, 10, 1026.	1.0	26
121	HLA-Mismatched Donors in Patients with Myelodysplastic Syndrome: An EBMT Registry Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 114-120.	2.0	27
122	Busulfan- or Thiotepa-Based Conditioning in Myelofibrosis: A Phase II Multicenter Randomized Study from the GITMO Group. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 932-940.	2.0	25
123	Cord blood transplantation is associated with good outcomes in secondary Acute Myeloid Leukaemia in first remission. <i>Journal of Internal Medicine</i> , 2019, 285, 446-454.	2.7	4
124	Impact of anti-thymocyte globulin on results of allogeneic peripheral blood stem cell transplantation for patients with Philadelphia-positive acute lymphoblastic leukaemia: An analysis by the Acute Leukemia Working Party of the EBMT. <i>European Journal of Cancer</i> , 2019, 106, 212-219.	1.3	13
125	IDH1-R132 changes vary according to NPM1 and other mutations status in AML. <i>Leukemia</i> , 2019, 33, 1043-1047.	3.3	17
126	PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2019, 51, 296-307.	9.4	384

#	ARTICLE	IF	CITATIONS
127	Effect of novel agents on the risk of early death of newly diagnosed symptomatic multiple myeloma patients: A single Centre retrospective analysis. American Journal of Hematology, 2019, 94, E11-E13.	2.0	2
128	Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet, The, 2019, 393, 229-240.	6.3	517
129	Evaluation and Counseling of Candidates. , 2019, , 77-86.		4
130	PS1458 RISK FACTORS AND OUTCOME OF ACUTE MYELOID LEUKEMIA SECONDARY TO POST-POLYCYTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: AN ANALYSIS OF THE MYSEC COHORT. HemaSphere, 2019, 3, 671.	1.2	2
131	A Phase I/II Study of NMS-03592088, a FLT3, KIT and CSF1R Inhibitor, in Patients with Relapsed or Refractory AML or CMML. Blood, 2019, 134, 3855-3855.	0.6	4
132	Identification of a Chromatin-Splicing Mutational Signature to Define Secondary Acute Myeloid Leukemia: A Report from the Northern Italy Leukemia Group (NILG) Prospective Trial 02/06. Blood, 2019, 134, 1443-1443.	0.6	1
133	Final Results of Prospective Treatment with Pegylated Interferon Alfa-2a for Patients with Polycythemia Vera and Essential Thrombocythemia in First and Second-Line Settings. Blood, 2019, 134, 2943-2943.	0.6	4
134	Outcomes Following Second Allogeneic Haematopoietic Cell Transplantation in Patients with Myelofibrosis: A Retrospective Study on Behalf of the Chronic Malignancies Working Party of EBMT. Blood, 2019, 134, 698-698.	0.6	1
135	Donor-Derived CD19 CAR Cytokine Induced Killer (CIK) Cells Engineered with Sleeping Beauty Transposon for Relapsed B-Cell Acute Lymphoblastic Leukemia (B-ALL). Blood, 2019, 134, 200-200.	0.6	5
136	Dasatinib-Blinatumomab Combination for the Front-Line Treatment of Adult Ph+ ALL Patients. Updated Results of the Gimema LAL2116 D-Alba Trial. Blood, 2019, 134, 740-740.	0.6	30
137	PF227ÂPROGNOSTIC VALUE OF CLONAL HEMATOPOIESISâ€MUTATIONS DETECTED AT DIAGNOSIS IN ACUTE MYELOID LEUKEMIA PATIENTS WITH NORMAL KARYOTYPE. HemaSphere, 2019, 3, 65-66.	1.2	0
138	PF436 GMP MANUFACTURING OF ALLOGENEIC CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) CYTOKINE INDUCED KILLER (CIK) CELLS WITH SLEEPING BEAUTY (SB) TRANSPOSON FOR ADOPTIVE IMMUNOTHERAPY. HemaSphere, 2019, 3, 171.	1.2	0
139	PF435 A FLEXIBLE THERAPEUTIC STRATEGY FOR LEUKEMIA USING EXâ€VIVO EXPANDED T CELLS COMBINED WITH BISPECIFIC ANTIBODIES. HemaSphere, 2019, 3, 170-171.	1.2	1
140	PS1257ÂLYMPHOCYTE TO MONOCYTE RATIO (LMR) PREDICTS PROGRESSIONâ€FREE SURVIVAL INDEPENDENTLY FROM FLIPI AND IS USEFUL IN IDENTIFYING PATIENTS WITH EARLY DISEASE PROGRESSION. HemaSphere, 2019, 3, 574-575.	1.2	0
141	Abstract 1324: NMS-P088, a novel FLT3, KIT and CSF1R inhibitor, is a promising clinical candidate for AML and CMML treatment. , 2019, , .		0
142	Treatment of Adults with Relapsed/Refractory Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia with Blinatumomab in a Real-World Setting: Results from the Neuf Study. Blood, 2019, 134, 2627-2627.	0.6	1
143	Outcome of Two Loci Mismatched (â‰¥6/8) Unrelated Donor Hematopoietic Cell Transplantation for Acute Leukemia: ALWP of the EBMT Study. Blood, 2019, 134, 4604-4604.	0.6	0
144	Treatment of Adults with Minimal Residual Disease (MRD) Positive Acute Lymphoblastic Leukemia with Blinatumomab in a Real-World Setting: Results from the Neuf Study. Blood, 2019, 134, 2624-2624.	0.6	1

#	ARTICLE	IF	CITATIONS
145	Impact of Bone Marrow Fibrosis Grade in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis. a Study of the Mysec Group. <i>Blood</i> , 2019, 134, 2946-2946.	0.6	0
146	Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion: Results from the National Registry of the Italian Drug Agency. <i>European Journal of Haematology</i> , 2018, 101, 78-85.	1.1	5
147	Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. <i>Haematologica</i> , 2018, 103, e392-e394.	1.7	31
148	Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts. <i>Leukemia</i> , 2018, 32, 1200-1210.	3.3	101
149	The spleen of patients with myelofibrosis harbors defective mesenchymal stromal cells. <i>American Journal of Hematology</i> , 2018, 93, 615-622.	2.0	8
150	Access to alternative donor hematopoietic search and transplantation for acute leukemia in different macro-regions of Italy. A GITMO/IBMDR study. <i>Bone Marrow Transplantation</i> , 2018, 53, 291-299.	1.3	4
151	Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia. <i>Leukemia Research</i> , 2018, 69, 100-102.	0.4	13
152	Phase I study of the heparanase inhibitor roneparstat: an innovative approach for ultiple myeloma therapy. <i>Haematologica</i> , 2018, 103, e469-e472.	1.7	90
153	Risk factors associated with development and mortality by invasive fungal diseases in pediatric allogeneic stem cell transplantation. A pediatric subgroup analysis of data from a prospective study of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). <i>Bone Marrow Transplantation</i> , 2018, 53, 1193-1197.	1.3	6
154	<i>TP53</i> in adult acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 778-789.	0.6	11
155	Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients. <i>Leukemia</i> , 2018, 32, 438-449.	3.3	26
156	Distinct factors determine the kinetics of disease relapse in adults transplanted for acute myeloid leukaemia. <i>Journal of Internal Medicine</i> , 2018, 283, 371-379.	2.7	19
157	Utility of routine evaluation of sterility of cellular therapy products with or without extensive manipulation: Best practices and clinical significance. <i>Cytotherapy</i> , 2018, 20, 262-270.	0.3	15
158	Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 507-513.	2.0	10
159	Targeting CDK6 and BCL2 Exploits the "MYB Addiction" of Ph+ Acute Lymphoblastic Leukemia. <i>Cancer Research</i> , 2018, 78, 1097-1109.	0.4	19
160	Mechanisms of Resistance to Targeted Therapies in Chronic Myeloid Leukemia. <i>Handbook of Experimental Pharmacology</i> , 2018, 249, 231-250.	0.9	15
161	Ruxolitinib-associated infections: A systematic review and meta-analysis. <i>American Journal of Hematology</i> , 2018, 93, 339-347.	2.0	164
162	Reply to H.J.A. Adams et al and C. Mesguich et al. <i>Journal of Clinical Oncology</i> , 2018, 36, 2125-2126.	0.8	2

#	ARTICLE	IF	CITATIONS
163	MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis. <i>Journal of Clinical Oncology</i> , 2018, 36, 310-318.	0.8	373
164	Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 454-462.	0.8	169
165	Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project. <i>Blood Cancer Journal</i> , 2018, 8, 89.	2.8	13
166	Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 1530-1542.	5.1	91
167	Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue. <i>Annals of Oncology</i> , 2018, 29, 2363-2370.	0.6	89
168	Targeting STAT5 or STAT5-Regulated Pathways Suppresses Leukemogenesis of Ph+ Acute Lymphoblastic Leukemia. <i>Cancer Research</i> , 2018, 78, 5793-5807.	0.4	17
169	Haploidentical transplantation is associated with better overall survival when compared to single cord blood transplantation: an EBMT-Eurocord study of acute leukemia patients conditioned with thiotepa, busulfan, and fludarabine. <i>Journal of Hematology and Oncology</i> , 2018, 11, 110.	6.9	41
170	Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , The, 2018, 391, 2116-2127.	6.3	79
171	Cord blood-derived cytokine-induced killer cells combined with blinatumomab as a therapeutic strategy for CD19+ tumors. <i>Cytotherapy</i> , 2018, 20, 1077-1088.	0.3	8
172	Umbilical Cord Blood Transplantation for Secondary AML: A Retrospective Study From the Acute Leukemia Working Party of the Ebmt and Eurocord. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S406.	2.0	0
173	The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting. <i>Blood Cancer Journal</i> , 2018, 8, 49.	2.8	30
174	Interim Results from Fight-203, a Phase 2, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Pemigatinib (INCB054828) in Patients with Myeloid/Lymphoid Neoplasms with Rearrangement of Fibroblast Growth Factor Receptor 1 (FGFR1). <i>Blood</i> , 2018, 132, 690-690.	0.6	26
175	Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial. <i>Blood</i> , 2018, 132, 3032-3032.	0.6	6
176	Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 Randomized Trial of Pegylated Interferon Alfa-2a (PEG) Versus Hydroxyurea (HU) Therapy for the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET). <i>Blood</i> , 2018, 132, 577-577.	0.6	39
177	Open-Label, Phase 2 Study of Blinatumomab As Second Salvage Therapy in Adults with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2018, 132, 400-400.	0.6	11
178	Molecular Subtypes of Splenic Marginal Zone Lymphoma (SMZL) Are Associated with Distinct Pathogenic Mechanisms and Outcomes - Interim Analysis of the IELSG46 Study. <i>Blood</i> , 2018, 132, 922-922.	0.6	2
179	Human Umbilical Cord Derived Mesenchymal Stromal Cells to Treat Steroid-Refractory Acute GvHD III/IV or Overlap Syndrome: Interim Analysis of a Multicenter Phase I/II Study. <i>Blood</i> , 2018, 132, 3404-3404.	0.6	1
180	Gimema Registry of Conception/Pregnancy in Adult Italian Patients Diagnosed with Chronic Myeloid Leukemia (CML): Report on 166 Outcomes. <i>Blood</i> , 2018, 132, 43-43.	0.6	10

#	ARTICLE	IF	CITATIONS
181	Evaluation of tenascin-C by tenatumomab in T-cell non-Hodgkin lymphomas identifies a new target for radioimmunotherapy. <i>Oncotarget</i> , 2018, 9, 9766-9775.	0.8	9
182	Characterization of Novel Subtypes in B Progenitor Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018, 132, 565-565.	0.6	14
183	High Resolution Donor/Recipient HLA Matching Level in Unrelated Hematopoietic Stem Cell Transplantation and Impact on the Transplant Outcome: The Italian Experience on Behalf of GITMO, IBMDR and Aibt. <i>Blood</i> , 2018, 132, 4642-4642.	0.6	0
184	Clinical-Grade Transduction of Allogeneic Cytokine Induced Killer (CIK) Cells with CD19 Chimeric Antigen Receptor (CAR) Using Sleeping Beauty (SB) Transposon: Successful GMP-Compliant Manufacturing for Clinical Applications. <i>Blood</i> , 2018, 132, 196-196.	0.6	0
185	Clinical Impact of an Accurate Genetic Characterization of Older Acute Myeloid Leukemia Patients: A Report from the Northern Italy Leukemia Group (NILG) Randomized Trial 02/06. <i>Blood</i> , 2018, 132, 434-434.	0.6	0
186	Permissive HLA-DPB1 Mismatch and Survival after Unrelated Donor Allogeneic Stem Cell Transplantation for Hematological Malignancies: A Comparative Analysis of Different Immunogenetic Models on 422 Patients from GITMO and IBMDR. <i>Blood</i> , 2018, 132, 482-482.	0.6	0
187	Impact of Upfront Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma with Del(17) and t(4;14): A Report from the EBMT Chronic Malignancies Working Party. <i>Blood</i> , 2018, 132, 2143-2143.	0.6	2
188	Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) and Lymphocyte to Monocyte Ratio (LMR) in Newly Diagnosed Advanced-Stage Hodgkin Lymphoma Patients Treated up-Front with a PET-2 Risk Adapted Protocol. <i>Blood</i> , 2018, 132, 2934-2934.	0.6	0
189	Solid Tumors in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis: A Study on 2220 Patients. <i>Blood</i> , 2018, 132, 3039-3039.	0.6	0
190	Factors predicting outcome after allogeneic transplant in refractory acute myeloid leukemia: a retrospective analysis of Gruppo Italiano Trapianto di Midollo Osseo (GITMO). <i>Bone Marrow Transplantation</i> , 2017, 52, 955-961.	1.3	20
191	Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms. <i>British Journal of Cancer</i> , 2017, 116, 335-343.	2.9	20
192	High-dose therapy and autologous stem cell transplantation in patients with POEMS syndrome: a retrospective study of the Plasma Cell Disorder sub-committee of the Chronic Malignancy Working Party of the European Society for Blood & Marrow Transplantation. <i>Haematologica</i> , 2017, 102, 160-167.	1.7	49
193	No correlation of intensity of phlebotomy regimen with risk of thrombosis in polycythemia vera: evidence from European Collaboration on Low-Dose Aspirin in Polycythemia Vera and Cytoreductive Therapy in Polycythemia Vera clinical trials. <i>Haematologica</i> , 2017, 102, e219-e221.	1.7	21
194	Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera. <i>Journal of Hematology and Oncology</i> , 2017, 10, 54.	6.9	41
195	Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. <i>New England Journal of Medicine</i> , 2017, 376, 836-847.	13.9	1,443
196	<i>CEBPA</i> "double-mutated acute myeloid leukemia displays a unique phenotypic profile: a reliable screening method and insight into biological features. <i>Haematologica</i> , 2017, 102, 529-540.	1.7	61
197	Validation of the acute leukemia EBMT score for prediction of mortality following allogeneic stem cell transplantation in a multi-center GITMO cohort. <i>American Journal of Hematology</i> , 2017, 92, 429-434.	2.0	33
198	High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults. <i>Journal of Clinical Oncology</i> , 2017, 35, 394-401.	0.8	326

#	ARTICLE	IF	CITATIONS
199	Allogeneic Stem Cell Transplantation for Relapsed/Refractory B Cell Lymphomas: Results of a Multicenter Phase II Prospective Trial including Rituximab in the Reduced-Intensity Conditioning Regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1102-1109.	2.0	9
200	Detection of driver and subclonal mutations in myelofibrosis: clinical impact on pharmacologic and transplant based treatment strategies. <i>Expert Review of Hematology</i> , 2017, 10, 627-636.	1.0	0
201	New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment?. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 821-836.	1.4	4
202	Radioimmunotherapy-augmented BEAM chemotherapy vs BEAM alone as the high-dose regimen for autologous stem cell transplantation (ASCT) in relapsed follicular lymphoma (FL): a retrospective study of the EBMT Lymphoma Working Party. <i>Bone Marrow Transplantation</i> , 2017, 52, 1120-1125.	1.3	8
203	A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. <i>Leukemia</i> , 2017, 31, 2726-2731.	3.3	242
204	Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group. <i>Haematologica</i> , 2017, 102, 85-93.	1.7	46
205	Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System. <i>Leukemia</i> , 2017, 31, 2449-2457.	3.3	51
206	Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study. <i>Annals of Oncology</i> , 2017, 28, 1547-1553.	0.6	46
207	Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis. <i>Blood</i> , 2017, 129, 3227-3236.	0.6	137
208	Tregs: hype or hope for allogeneic hematopoietic stem cell transplantation?. <i>Bone Marrow Transplantation</i> , 2017, 52, 1225-1232.	1.3	12
209	PML-RARA-associated cooperating mutations belong to a transcriptional network that is deregulated in myeloid leukemias. <i>Leukemia</i> , 2017, 31, 1975-1986.	3.3	10
210	In Adult Acute Lymphoblastic Leukemia End of Induction MRD Correlates Strongly with Subsequent Key Timepoints and Predicts Long Term Outcome. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S262-S263.	0.2	0
211	Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results. <i>Blood</i> , 2017, 130, 1768-1771.	0.6	52
212	Tumour-derived PGD2 and Nkp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis. <i>Nature Communications</i> , 2017, 8, 593.	5.8	175
213	Clinical Phenotype and Genotype Correlations with Time to Progression into Post Polycythemia Vera and Post Essential Thrombocythemia Myelofibrosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S354-S355.	0.2	0
214	Phase II Study of Sequential Infusion of Donor Lymphocyte Infusion and Cytokine-Induced Killer Cells for Patients Relapsed after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 2070-2078.	2.0	48
215	Heavy+Light Chain and Free Light Chain Assays at Baseline and During Follow-up in EMN02/HO95 Multiple Myeloma Clinical Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e47.	0.2	0
216	Minimal Residual Disease Assessment and Risk-based Therapy in Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S2-S9.	0.2	20

#	ARTICLE	IF	CITATIONS
217	TAK-659, AN INVESTIGATIONAL REVERSIBLE DUAL SYK/FLT-3 INHIBITOR, IN PATIENTS WITH LYMPHOMA: UPDATED RESULTS FROM DOSE-ESCALATION AND EXPANSION COHORTS OF a PHASE 1 STUDY. <i>Hematological Oncology</i> , 2017, 35, 72-74.	0.8	5
218	Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs. <i>Leukemia Research</i> , 2017, 63, 34-40.	0.4	18
219	Inflammation and myeloproliferative neoplasms. <i>Journal of Autoimmunity</i> , 2017, 85, 58-63.	3.0	102
220	Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation—a position paper. <i>Clinical Microbiology and Infection</i> , 2017, 23, 935-940.	2.8	69
221	Autologous stem cell transplantation is still a valid option in good- and intermediate-risk AML: a GITMO survey on 809 patients autografted in first complete remission. <i>Bone Marrow Transplantation</i> , 2017, 52, 163-166.	1.3	24
222	The effect of arterial hypertension on thrombosis in low-risk polycythemia vera. <i>American Journal of Hematology</i> , 2017, 92, E5-E6.	2.0	45
223	Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 605-612.	0.8	299
224	The EBMT-ELN working group recommendations on the prophylaxis and treatment of GvHD: a change-control analysis. <i>Bone Marrow Transplantation</i> , 2017, 52, 357-362.	1.3	13
225	Safety and efficacy of ruxitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms. <i>American Journal of Hematology</i> , 2017, 92, 187-195.	2.0	41
226	Driver mutations™ effect in secondary myelofibrosis: an international multicenter study based on 781 patients. <i>Leukemia</i> , 2017, 31, 970-973.	3.3	41
227	Safety and efficacy of thiotepa-based conditioning for allogeneic transplantation in AML: a survey from the ALWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2017, 52, 238-244.	1.3	15
228	Incidence, Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia After Allogeneic and Autologous Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey. <i>Clinical Infectious Diseases</i> , 2017, 65, 1884-1896.	2.9	103
229	Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 1795-1802.	0.8	348
230	RAR \pm 2 and PML-RAR similarities in the control of basal and retinoic acid induced myeloid maturation of acute myeloid leukemia cells. <i>Oncotarget</i> , 2017, 8, 37041-37060.	0.8	8
231	Abstract CT057: Phase 2, open-label, multicenter study to evaluate the efficacy and safety of INCB054828 in patients with myeloid/lymphoid neoplasms with fibroblast growth factor receptor 1 (FGFR1) rearrangement. , 2017, , .		0
232	IS THERE A ROLE FOR MINIMAL RESIDUAL DISEASE MONITORING IN FOLLICULAR LYMPHOMA IN THE CHEMO-IMMUNOTHERAPY ERA?. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2016, 9, e2017010.	0.5	9
233	Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients. <i>American Journal of Hematology</i> , 2016, 91, 918-922.	2.0	47
234	Allogeneic hematopoietic cell transplantation in acute myeloid leukemia with normal karyotype and isolated Nucleophosmin-1 (NPM1) mutation: outcome strongly correlates with disease status. <i>Haematologica</i> , 2016, 101, e34-e37.	1.7	12

#	ARTICLE	IF	CITATIONS
235	Mutations of TP53 gene in adult acute lymphoblastic leukemia at diagnosis do not affect the achievement of hematologic response but correlate with early relapse and very poor survival. <i>Haematologica</i> , 2016, 101, e245-e248.	1.7	29
236	Allo-HCT regimens with low toxicity needed in older patients with acute myeloid leukaemia – Authors' reply. <i>Lancet Oncology</i> , The, 2016, 17, e1-e2.	5.1	0
237	PO-26 - Whole blood rotational thromboelastometry (ROTEM) to detect hypercoagulability in patients with myeloproliferative neoplasms (MPN). <i>Thrombosis Research</i> , 2016, 140, S185-S186.	0.8	11
238	Outcomes of Hematopoietic Stem Cell Transplantation (HSCT) Among Adults with Relapsed/Refractory (r/r) Acute Lymphoblastic Leukemia (ALL) Achieving Remission with Blinatumomab. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S35-S36.	2.0	2
239	Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2016, 34, 3627-3637.	0.8	204
240	Feasibility of Allogeneic Stem Cell Transplantation After Azacitidine in Patients with High Risk Myelodysplastic Syndromes or Low-Blast Count Acute Myeloid Leukemias: the Experience of the BMT-AZA Multicenter Prospective Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, S83-S84.	0.2	0
241	Randomized Trial Comparing R-CHOP Versus High-Dose Sequential Chemotherapy in High-Risk Patients With Diffuse Large B-Cell Lymphomas. <i>Journal of Clinical Oncology</i> , 2016, 34, 4015-4022.	0.8	66
242	Achieving Molecular Remission before Allogeneic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Impact on Relapse and Long-Term Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1983-1987.	2.0	77
243	Health-related quality of life and burden of fatigue in patients with primary immune thrombocytopenia by phase of disease. <i>American Journal of Hematology</i> , 2016, 91, 995-1001.	2.0	53
244	Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group. <i>American Journal of Hematology</i> , 2016, 91, 681-686.	2.0	80
245	Integrative analysis of copy number and gene expression data suggests novel pathogenetic mechanisms in primary myelofibrosis. <i>International Journal of Cancer</i> , 2016, 138, 1657-1669.	2.3	6
246	Risk-adapted Treatment for Severe B-Lineage Posttransplant Lymphoproliferative Disease After Solid Organ Transplantation in Children. <i>Transplantation</i> , 2016, 100, 437-445.	0.5	14
247	PO-19 - Platelet (PLT) adhesion under flow condition in essential thrombocythemia (ET) and polycythemia vera (PV) is variably influenced according to patient mutational status. <i>Thrombosis Research</i> , 2016, 140, S183.	0.8	1
248	Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease. <i>Journal of Clinical Oncology</i> , 2016, 34, 151-159.	0.8	56
249	Reduced intensity allogeneic stem cell transplantation for follicular lymphoma relapsing after an autologous transplant achieves durable long-term disease control: an analysis from the Lymphoma Working Party of the EBMT. <i>Annals of Oncology</i> , 2016, 27, 1088-1094.	0.6	29
250	Rabbit anti-thymocyte globulin to prevent GVHD. <i>Lancet Oncology</i> , The, 2016, 17, 124-125.	5.1	1
251	Association of <i>CFHR1</i> homozygous deletion with acute myelogenous leukemia in the European population. <i>Leukemia and Lymphoma</i> , 2016, 57, 1234-1237.	0.6	5
252	Final Analysis of a Multicenter Pilot Phase 2 Study of Cytokine Induced Killer (CIK) Cells for Patients with Relapse after Allogeneic Transplantation. <i>Blood</i> , 2016, 128, 1160-1160.	0.6	5

#	ARTICLE	IF	CITATIONS
253	Final Results of Northern Italy Leukemia Group (NILG) Trial 10/07 Combining Pediatric-Type Therapy with Minimal Residual Disease Study and Risk-Oriented Hematopoietic Cell Transplantation in Adult Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2016, 128, 176-176.	0.6	21
254	Health Related Quality of Life of Long-Term Survivors of Acute Promyelocytic Leukemia Treated with All-Trans Retinoic Acid and Chemotherapy. <i>Blood</i> , 2016, 128, 2415-2415.	0.6	3
255	Symptom Burden As Primary Driver for Therapy in Patients with Myelofibrosis: An Analysis By MPN International Quality of Life Study Group. <i>Blood</i> , 2016, 128, 3117-3117.	0.6	4
256	A PHASE 1/2 Clinical Trial of Brentuximab-Vedotin and Bendamustin in Elderly Patients with Previously Untreated Advanced Hodgkin Lymphoma (HALO STUDY. NCT identifier : 02467946): Preliminary Report. <i>Blood</i> , 2016, 128, 4154-4154.	0.6	5
257	A Two-Part Study of Givinostat in Patients with Polycythemia Vera: Maximum Tolerated Dose Definition and Preliminary Efficacy Results. <i>Blood</i> , 2016, 128, 4261-4261.	0.6	6
258	Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Interim Analysis Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial. <i>Blood</i> , 2016, 128, 4271-4271.	0.6	5
259	Interim Analysis of the Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia. <i>Blood</i> , 2016, 128, 479-479.	0.6	32
260	Updated Results from a Phase 1 Study of TAK-659, an Investigational and Reversible SYK Inhibitor, in Patients (Pts) with Advanced Solid Tumor or Lymphoma Malignancies. <i>Blood</i> , 2016, 128, 624-624.	0.6	8
261	JAK2V617F Mutation and Thrombosis History Are Determinants of Mean Platelet Volume (MPV) in Essential Thrombocythemia Patients. <i>Blood</i> , 2016, 128, 2606-2606.	0.6	0
262	Autologous Versus Related Versus Unrelated Hematopoietic Stem Cell Transplantation for Adult Patients with NPM1 Mutated/FLT3-ITD Negative Acute Myeloid Leukemia in First Remission: A Study from the Acute Leukemia Working Party (ALWP) of the European Society of Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2016, 128, 2279-2279.	0.6	1
263	Tenascin-C Is Highly Expressed in T-Cell Non-Hodgkin Lymphomas and Represents an Attractive Target for Radioimmunotherapy. <i>Blood</i> , 2016, 128, 4141-4141.	0.6	1
264	Characterization of Factors Determining the Kinetics of Disease Relapse after Allogeneic Stem Cell Transplantation (allo-SCT) or Chemotherapeutic Consolidation for Acute Myeloid Leukaemia (AML) in First CR: A Survey from HOVON-SAKK and the Acute Leukaemia Working Party of the EBMT. <i>Blood</i> , 2016, 128, 3467-3467.	0.6	0
265	Consideration of Symptom Burden Based Treatment in PV and ET Patients: An Analysis By MPN International Quality of Life Study Group. <i>Blood</i> , 2016, 128, 5463-5463.	0.6	0
266	Prediction of Allogeneic Stem Cell Transplantation Mortality in Patients with Acute Leukemia (AL) Using the AL- European Society for Blood and Marrow Transplantation (EBMT) Risk Score in the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO) Data Set: A Study on Behalf of the AL Working Party (ALWP) of the EBMT and GITMO. <i>Blood</i> , 2016, 128, 989-989.	0.6	0
267	Effects of Antiplatelet Treatment with Aspirin (ASA) on Platelet Reactivity in Patients with Essential Thrombocythemia. <i>Blood</i> , 2016, 128, 4253-4253.	0.6	0
268	Final Results of a Multicenter Prospective Phase II Trial of Allogeneic Transplantation for Relapsed/Refractory CD20+ B-Cell Lymphomas: Effect of Rituximab on Graft-Versus-Host Disease-Free/Relapse-Free Survival (GRFS). <i>Blood</i> , 2016, 128, 3473-3473.	0.6	0
269	Hevylite and Freelite Tests in Newly Diagnosed Multiple Myeloma: Clinical Utility and Correlations with Clinical Features. <i>Blood</i> , 2016, 128, 5625-5625.	0.6	0
270	Driver Somatic Mutations and Transplantation Decision Making in Patients with Myelodysplastic Syndrome. <i>Blood</i> , 2016, 128, 53-53.	0.6	0

#	ARTICLE	IF	CITATIONS
271	Differences in Clinical and Molecular Characteristics and Outcome in Prefibrotic and Overt Primary Myelofibrosis According to 2016 WHO Criteria. a Study on 639 Patients of the Agimm Group. <i>Blood</i> , 2016, 128, 943-943.	0.6	1
272	Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO criteria and stratified by calendar period of diagnosis. <i>American Journal of Hematology</i> , 2015, 90, 434-437.	2.0	19
273	Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. <i>Blood Cancer Journal</i> , 2015, 5, e369-e369.	2.8	188
274	White blood cell counts and thrombosis in polycythemia vera: a subanalysis of the CYTO-PV study. <i>Blood</i> , 2015, 126, 560-561.	0.6	82
275	A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients. <i>Haematologica</i> , 2015, 100, e501-e504.	1.7	22
276	Randomized trial of radiation-free central nervous system prophylaxis comparing intrathecal triple therapy with liposomal cytarabine in acute lymphoblastic leukemia. <i>Haematologica</i> , 2015, 100, 786-793.	1.7	27
277	Economics and Outcome After Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study. <i>EBioMedicine</i> , 2015, 2, 2101-2109.	2.7	36
278	Second allogeneic stem cell transplant for aplastic anaemia: a retrospective study by the severe aplastic anaemia working party of the European society for blood and marrow transplantation. <i>British Journal of Haematology</i> , 2015, 171, 606-614.	1.2	27
279	Mesenchymal stromal cells for prevention and treatment of graft-versus-host disease. <i>Current Opinion in Organ Transplantation</i> , 2015, 20, 72-78.	0.8	48
280	Autologous hematopoietic stem cell transplantation in multiple sclerosis. <i>Neurology</i> , 2015, 84, 981-988.	1.5	201
281	Unrelated cord blood transplantation for adult patients with acute myeloid leukemia: higher incidence of acute graft-versus-host disease and lower survival in male patients transplanted with female unrelated cord blood—a report from Eurocord, the Acute Leukemia Working Party, and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the European Group for Blood and Marrow Transplantation. <i>Journal of Clinical Oncology</i> , 2015, 33, 107.	6.9	35
282	Mobilization of peripheral blood hematopoietic stem cells by granulocyte-colony stimulating factor and plerixafor in patients with cardiac AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2015, 22, 259-260.	1.4	2
283	Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2015, 16, 57-66.	5.1	1,031
284	Differences among young adults, adults and elderly chronic myeloid leukemia patients. <i>Annals of Oncology</i> , 2015, 26, 185-192.	0.6	72
285	Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy. <i>Haematologica</i> , 2015, 100, 77-86.	1.7	147
286	Consensus recommendations for improvement of unmet clinical needs—the example of chronic graft-versus-host disease: a systematic review and meta-analysis. <i>Lancet Haematology</i> , the, 2015, 2, e297-e305.	2.2	16
287	Management of carbapenem resistant <i>Klebsiella pneumoniae</i> infections in stem cell transplant recipients: an Italian multidisciplinary consensus statement. <i>Haematologica</i> , 2015, 100, e373-e376.	1.7	44
288	Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia. <i>Haematologica</i> , 2015, 100, 392-399.	1.7	139

#	ARTICLE	IF	CITATIONS
289	Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 1525-1536.	5.1	143
290	Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients. <i>Leukemia Research</i> , 2015, 39, 1055-1059.	0.4	57
291	Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group. <i>Leukemia</i> , 2015, 29, 2126-2133.	3.3	242
292	Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. <i>New England Journal of Medicine</i> , 2015, 373, 1733-1747.	13.9	281
293	Design and Validation of an Augmented Hematopoietic Cell Transplantation-Comorbidity Index Comprising Pretransplant Ferritin, Albumin, and Platelet Count for Prediction of Outcomes after Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1418-1424.	2.0	62
294	Rare High Risk IgH Translocations in Newly Diagnosed Multiple Myeloma (MM): Cytogenetic Characterization and Relevance on Prognosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, e46-e47.	0.2	0
295	CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis. <i>Leukemia</i> , 2015, 29, 1209-1210.	3.3	31
296	Infections by carbapenem-resistant <i>Klebsiella pneumoniae</i> in SCT recipients: a nationwide retrospective survey from Italy. <i>Bone Marrow Transplantation</i> , 2015, 50, 282-288.	1.3	142
297	Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation Guidelines for the Management of Indolent, Nonfollicular B-Cell Lymphoma (Marginal Zone, Lymphoplasmacytic, and Small Lymphocytic Lymphoma). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 75-85.	0.2	32
298	Cell-based strategies to manage leukemia relapse: efficacy and feasibility of immunotherapy approaches. <i>Leukemia</i> , 2015, 29, 1-10.	3.3	54
299	High Frequency and Poor Outcome of Ph-like Acute Lymphoblastic Leukemia in Adults. <i>Blood</i> , 2015, 126, 2618-2618.	0.6	5
300	Long Term Follow up of a Phase 2 Study of Ruxolitinib in Patients with Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasm. <i>Blood</i> , 2015, 126, 2803-2803.	0.6	2
301	A Multicenter Phase II Study of Sequential Administration of Unmanipulated DLI and Donor Derived Cytokine Induced Killer (CIK) Cells in HSCT Patients, Relapsed of Disease. <i>Blood</i> , 2015, 126, 3160-3160.	0.6	3
302	Allogeneic Hematopoietic Cell Transplantation for Adult Patients with ALL: Current Results and Prognostic Factors. an Analysis from Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2015, 126, 3202-3202.	0.6	1
303	Roneparstat (SST0001), an Innovative Heparanase (HPSE) Inhibitor for Multiple Myeloma (MM) Therapy: First in Man Study. <i>Blood</i> , 2015, 126, 3246-3246.	0.6	10
304	Prognostic Impact of Bone Marrow Fibrosis in Primary Myelofibrosis: A Study of Agimm Group on 540 Patients. <i>Blood</i> , 2015, 126, 351-351.	0.6	1
305	Life Expectancy in Follicular Lymphoma Is Mainly Determined By Response to First LINE Treatment: A LONG-TERM Survey on 597 Patients. <i>Blood</i> , 2015, 126, 3989-3989.	0.6	3
306	Impact of Disease Duration upon Symptom Burden Amongst Patients with Myeloproliferative Neoplasms (MPNs). <i>Blood</i> , 2015, 126, 4073-4073.	0.6	2

#	ARTICLE	IF	CITATIONS
307	Symptom Burden Profile in Myelofibrosis Patients with Thrombocytopenia: Lessons and Unmet Needs. <i>Blood</i> , 2015, 126, 4080-4080.	0.6	3
308	Feasibility of Azacitidine As Bridge to Allogeneic Stem Cell Transplantation in Patients with Higher-Risk MDS or Low-Blast Count AML: Results of the BMT-AZA Multicenter Prospective Study. <i>Blood</i> , 2015, 126, 66-66.	0.6	2
309	Treatment with Anti-CD19 BiTE [®] Blinatumomab in Adult Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (r/r ALL) Post-Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 861-861.	0.6	4
310	Primary Treatment Response Rather than Front Line Stem Cell Transplantation Is Crucial for Long Term Outcome of Peripheral T-Cell Lymphomas. <i>PLoS ONE</i> , 2015, 10, e0121822.	1.1	9
311	Use of Lenalidomide in DEL(5q) MDS. a National AIFA (Agenzia Italiana del Farmaco) Registry Study. <i>Blood</i> , 2015, 126, 1693-1693.	0.6	1
312	Unmet Needs for Symptom Control in Essential Thrombocythemia with Front Line Therapy. <i>Blood</i> , 2015, 126, 5175-5175.	0.6	0
313	Platelet Adhesion Under Flow Condition in Patients with Essential Thrombocythemia (ET) and Polycythemia Vera (PV): Analysis According to the Mutational Status. <i>Blood</i> , 2015, 126, 766-766.	0.6	0
314	Levels of Minimal Residual Disease Prior to Transplant Influence Outcome of Adult Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015, 126, 4374-4374.	0.6	0
315	Health-Related Quality of Life in Patients with Primary Immune Thrombocytopenia (pITP): Investigating Differences Amongst Newly Diagnosed, Persistent and Chronic Pitp Patients. <i>Blood</i> , 2015, 126, 2122-2122.	0.6	0
316	Impact of Comorbidity Burden in Treatment and Outcome of Older Patients with Indolent Non-Hodgkin Lymphomas. <i>Blood</i> , 2015, 126, 4503-4503.	0.6	0
317	Practice-Relevant Revision of Ispet-Thrombosis Based on 1019 Patients with WHO-Defined Essential Thrombocythemia. <i>Blood</i> , 2015, 126, 4055-4055.	0.6	0
318	Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma. <i>Transfusion</i> , 2014, 54, 331-339.	0.8	39
319	PROGNOSTIC SIGNIFICANCE AND TREATMENT IMPLICATIONS OF MINIMAL RESIDUAL DISEASE STUDIES IN PHILADELPHIA-NEGATIVE ADULT ACUTE LYMPHOBLASTIC LEUKEMIA. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2014, 6, e2014062.	0.5	11
320	Simple, rapid and accurate molecular diagnosis of acute promyelocytic leukemia by loop mediated amplification technology. <i>Oncoscience</i> , 2014, 2, 50-58.	0.9	15
321	Frequent occurrence of non-malignant genetic alterations in clinical grade mesenchymal stromal cells expanded for cell therapy protocols. <i>Haematologica</i> , 2014, 99, e94-e97.	1.7	29
322	Different molecular levels of post-induction minimal residual disease may predict hematopoietic stem cell transplantation outcome in adult Philadelphia-negative acute lymphoblastic leukemia. <i>Blood Cancer Journal</i> , 2014, 4, e225-e225.	2.8	57
323	Comparison of outcomes after single or double cord blood transplantation in adults with acute leukemia using different types of myeloablative conditioning regimen, a retrospective study on behalf of Eurocord and the Acute Leukemia Working Party of EBMT. <i>Leukemia</i> , 2014, 28, 779-786.	3.3	95
324	Prognostic impact of minimal residual disease in adult acute lymphoblastic leukemia. <i>International Journal of Hematologic Oncology</i> , 2014, 3, 419-431.	0.7	0

#	ARTICLE	IF	CITATIONS
325	Highly aggressive T-cell acute lymphoblastic leukemia with t(8;14)(q24;q11): extensive genetic characterization and achievement of early molecular remission and long-term survival in an adult patient. <i>Blood Cancer Journal</i> , 2014, 4, e176-e176.	2.8	8
326	Quality of harvest and role of cell dose in unrelated bone marrow transplantation: An Italian Bone Marrow Donor Registryâ€“Gruppo Italiano Trapianto di Midollo Osseo Study. <i>Hematology</i> , 2014, 19, 1-9.	0.7	10
327	A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. <i>Cancer</i> , 2014, 120, 513-520.	2.0	165
328	Masked polycythemia vera diagnosed according to WHO and BCSH classification. <i>American Journal of Hematology</i> , 2014, 89, 199-202.	2.0	64
329	Cerebral vein thrombosis in patients with Philadelphiaâ€“negative myeloproliferative neoplasms An European Leukemia Network study. <i>American Journal of Hematology</i> , 2014, 89, E200-5.	2.0	42
330	Phospholipidâ€“dependent procoagulant activity is highly expressed by circulating microparticles in patients with essential thrombocythemia. <i>American Journal of Hematology</i> , 2014, 89, 68-73.	2.0	53
331	Direct involvement of CD56 in cytokine-induced killerâ€“mediated lysis of CD56+ hematopoietic target cells. <i>Experimental Hematology</i> , 2014, 42, 1013-1021.e1.	0.2	31
332	Myeloblastic therapy with autologous haematopoietic stem cell support as consolidation of first remission in acute myeloid leukaemia â€“ very long follow-up. <i>British Journal of Haematology</i> , 2014, 167, 724-726.	1.2	4
333	A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera. <i>British Journal of Haematology</i> , 2014, 167, 541-546.	1.2	47
334	Kinetics of the use of cryopreserved autologous stem cell grafts: a GITMO-SIDEM survey. <i>Cytotherapy</i> , 2014, 16, 101-110.	0.3	6
335	JACIE accreditation status and outcome after hematopoietic stem cell transplantation. <i>Cytotherapy</i> , 2014, 16, S11.	0.3	0
336	Early-stage diffuse large B cell lymphoma of the head and neck: clinico-biological characterization and 18-year follow-up of 488 patients (IELSG 23 study). <i>Annals of Hematology</i> , 2014, 93, 221-231.	0.8	36
337	Expertsâ€™ considerations on HLAâ€“haploidentical stem cell transplantation. <i>European Journal of Haematology</i> , 2014, 93, 187-197.	1.1	24
338	Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients. <i>American Journal of Hematology</i> , 2014, 89, 588-590.	2.0	75
339	Masked polycythemia Vera (mPV): Results of an international study. <i>American Journal of Hematology</i> , 2014, 89, 52-54.	2.0	130
340	Treatment of Graft versus Host Disease with Mesenchymal Stromal Cells: A Phase I Study on 40 Adult and Pediatric Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 375-381.	2.0	181
341	Results of a randomized trial comparing high-dose chemotherapy plus Auto-SCT and R-FC in CLL at diagnosis. <i>Bone Marrow Transplantation</i> , 2014, 49, 485-491.	1.3	10
342	A Novel Method Using Blinatumomab for Efficient, Clinical-Grade Expansion of Polyclonal T Cells for Adoptive Immunotherapy. <i>Journal of Immunology</i> , 2014, 193, 4739-4747.	0.4	24

#	ARTICLE	IF	CITATIONS
343	Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma. <i>Leukemia</i> , 2014, 28, 1885-1891.	3.3	83
344	A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphoma. <i>Annals of Oncology</i> , 2014, 25, 2398-2404.	0.6	14
345	Primary Prophylaxis of Invasive Fungal Diseases in Allogeneic Stem Cell Transplantation: Revised Recommendations from a Consensus Process by Gruppo Italiano Trapianto Midollo Osseo (GITMO). <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1080-1088.	2.0	54
346	Incidence and Outcome of Invasive Fungal Diseases after Allogeneic Stem Cell Transplantation: A Prospective Study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 872-880.	2.0	141
347	Impact of Cytomegalovirus Replication and Cytomegalovirus Serostatus on the Outcome of Patients with B Cell Lymphoma after Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 885-890.	2.0	42
348	Identifying and addressing unmet clinical needs in Ph-neg classical myeloproliferative neoplasms: A consensus-based SIE, SIES, GITMO position paper. <i>Leukemia Research</i> , 2014, 38, 155-160.	0.4	28
349	Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. <i>Haematologica</i> , 2014, 99, 916-921.	1.7	62
350	ROLE OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2014, 6, e2014065.	0.5	8
351	MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis. <i>Blood</i> , 2014, 124, 1183-1191.	0.6	135
352	Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. <i>Blood</i> , 2014, 124, 2507-2513.	0.6	575
353	Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients. <i>Blood</i> , 2014, 123, 3803-3810.	0.6	79
354	Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R. <i>Blood</i> , 2014, 123, 2333-2342.	0.6	162
355	miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells: role of miR-155/JARID2 axis in abnormal megakaryopoiesis. <i>Blood</i> , 2014, 124, e21-e32.	0.6	105
356	In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. <i>Blood</i> , 2014, 124, 3021-3023.	0.6	112
357	Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia. <i>Blood</i> , 2014, 124, 2611-2612.	0.6	79
358	Efficacy and Safety of the BRAF Inhibitor Vemurafenib in Hairy Cell Leukemia Patients Refractory to or Relapsed after Purine Analogs: A Phase-2 Italian Clinical Trial. <i>Blood</i> , 2014, 124, 150-150.	0.6	4
359	Post-Polycythemia and Post-Thrombocythemia Myelofibrosis Have Distinctive Clinical Phenotypes: An International Multicenter Study on 718 Patients. <i>Blood</i> , 2014, 124, 1824-1824.	0.6	9
360	Long-Term Results from a Phase II Open-Label Study of Ruxolitinib in Patients with Essential Thrombocythemia Refractory to or Intolerant of Hydroxyurea. <i>Blood</i> , 2014, 124, 1847-1847.	0.6	14

#	ARTICLE	IF	CITATIONS
361	Symptom Severity and Clinical Variables of Polycythemia Vera Patients with Splenomegaly, Phlebotomy Requirements and/or Hydroxyurea Use: a Retrospective Evaluation of 1334 Patients. <i>Blood</i> , 2014, 124, 1848-1848.	0.6	2
362	Towards a Better Understanding of Epidemiology, Survival and Treatment in Myeloproliferative Neoplasms: Results of the European Leukemianet Registry (ERNEST study). <i>Blood</i> , 2014, 124, 1849-1849.	0.6	4
363	Rare Igh Translocations in Newly Diagnosed Multiple Myeloma (MM) Patients: Cytogenetic Characterization and Relevance on Prognosis. <i>Blood</i> , 2014, 124, 2042-2042.	0.6	1
364	Role of Allogeneic Stem Cell Transplantation (AlloSCT) in Patients Affected By Peripheral T-Cell Lymphomas (PTCL): No Difference in Outcome Between Patients Allografted at Diagnosis and in First Chemosensitive Relapse. <i>Blood</i> , 2014, 124, 2574-2574.	0.6	1
365	A Phase 2 Study of Ruxolitinib in Patients with Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasm: A Study from the AGIMM Group. <i>Blood</i> , 2014, 124, 3192-3192.	0.6	1
366	Chronic Graft-Versus-Host Disease after Allogeneic Stem Cell Transplant with in Vivo T-Cell Depletion By Alemtuzumab: Incidence, Outcome and Pattern of Organ Involvement. <i>Blood</i> , 2014, 124, 3912-3912.	0.6	1
367	Allogeneic HCT with Reduced Intensity Conditioning Versus Autologous HCT for >55 Years Old Patients with Acute Lymphoblastic Leukemia in First Complete Remission: An Analysis from Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2014, 124, 3974-3974.	0.6	2
368	Mutation-Enhanced International Prognostic Scoring System (MIPSS) for Primary Myelofibrosis: An AGIMM & IWG-MRT Project. <i>Blood</i> , 2014, 124, 405-405.	0.6	47
369	Acute Myeloid Leukemia Relapses after Allogeneic HSCT Display a Distinctive Immune-Related Signature, with Frequent and Functionally Relevant Alterations in HLA Class II Antigen Presentation and T Cell Costimulation. <i>Blood</i> , 2014, 124, 427-427.	0.6	9
370	Decision Analysis of Allogeneic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome Stratified According to the Revised International Prognostic Scoring System (IPSS-R). <i>Blood</i> , 2014, 124, 531-531.	0.6	2
371	Randomized Trial of Busulfan with Cyclophosphamide Versus Busulfan with Fludarabine As Preparative Regimen to Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia: A Study from the Gruppo Italiano Trapianto Midollo Osseo (GITMO). <i>Blood</i> , 2014, 124, 727-727.	0.6	1
372	Allogeneic Hematopoietic Stem Cell Transplantation Following Anti-CD19 BiTE [®] Blinatumomab in Adult Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2014, 124, 965-965.	0.6	6
373	Rate of Primary Refractory Disease in B and T-Cell Non-Hodgkin's Lymphoma: Correlation with Long-Term Survival. <i>PLoS ONE</i> , 2014, 9, e106745.	1.1	18
374	Genomic quantitative real-time PCR proves residual disease positivity in more than 30% samples with negative mRNA-based qRT-PCR in Chronic Myeloid Leukemia. <i>Oncoscience</i> , 2014, 1, 510-521.	0.9	32
375	Identification of kitM541L somatic mutation in chronic eosinophilic leukemia, not otherwise specified and its implication in low-dose imatinib response. <i>Oncotarget</i> , 2014, 5, 4665-4670.	0.8	28
376	Updating Long-Term Outcome of Intermittent Imatinib (INTERIM) Treatment in Elderly Patients with Ph ⁺ -CML. <i>Blood</i> , 2014, 124, 1794-1794.	0.6	1
377	Safety and Efficacy of Thiotepa-Based Conditioning Therapy for Allogeneic Transplantation in Acute Myeloid Leukemia - a Survey from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Blood</i> , 2014, 124, 3895-3895.	0.6	0
378	Factors Predicting Outcome after Allogeneic Stem Cell Transplantation in Primary Refractory Acute Myeloid Leukemia: A Retrospective Analysis of the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO). <i>Blood</i> , 2014, 124, 731-731.	0.6	0

#	ARTICLE	IF	CITATIONS
379	Contrasting Factors Determine the Kinetics of Disease Relapse after Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myeloid Leukaemia (AML): a Survey from the Acute Leukaemia Working Party of the EBMT. <i>Blood</i> , 2014, 124, 3945-3945.	0.6	0
380	Next Generation Sequencing (NGS) of TP53 Gene Allows to Identify a Very High Risk Group of Philadelphia Negative Acute Lymphoblastic Leukemia (ALL) Patients. <i>Blood</i> , 2014, 124, 3796-3796.	0.6	0
381	Pre-Transplant Ferritin, Albumin and Platelet Count Add Prognostic Information to Comorbidities for Allogeneic Hematopoietic Cell Transplantation (HCT) Outcomes: A Multi-Center Discovery-Validation Study. <i>Blood</i> , 2014, 124, 421-421.	0.6	1
382	Calreticulin Mutation Is Associated with Milder Disease in Patients with Post Essential Thrombocythemia Myelofibrosis (PET-MF) Compared with JAK2V617F Mutation: A Study from the AGIMM Group. <i>Blood</i> , 2014, 124, 3179-3179.	0.6	0
383	Calreticulin Mutation Does Not Modify the International Prognostic Score for Predicting the Risk of Thrombosis Among 1,150 Patients with Essential Thrombocythemia. <i>Blood</i> , 2014, 124, 404-404.	0.6	0
384	Impact of Mutation Status of ASXL1, EZH2, SRSF2, IDH1/2 on Clinical Phenotype and Prognosis in Patients with Post-Polycythemia and Post-Essential Thrombocythemia Myelofibrosis: An AGIMM Study. <i>Blood</i> , 2014, 124, 1867-1867.	0.6	0
385	Allogeneic Hematopoietic Cell Transplantation in AML with Normal Karyotype and NPM1 Mutated FLT3-ITD Negative: A Retrospective Analysis from the Acute Leukemia Working Party of EBMT. <i>Blood</i> , 2014, 124, 1230-1230.	0.6	1
386	ADP-induced platelet aggregation and thrombin generation are increased in Essential Thrombocythemia and Polycythemia Vera. <i>Thrombosis Research</i> , 2013, 132, 88-93.	0.8	41
387	Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia. <i>New England Journal of Medicine</i> , 2013, 369, 111-121.	13.9	1,284
388	A phase II study of <i>ganitumab</i> in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy. <i>British Journal of Haematology</i> , 2013, 161, 688-694.	1.2	109
389	Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome. <i>American Journal of Hematology</i> , 2013, 88, 581-588.	2.0	61
390	Cytokine Induced Killer (CIK) cells for the treatment of haematological neoplasms. <i>Immunology Letters</i> , 2013, 155, 27-30.	1.1	30
391	Mutations and chromosomal rearrangements of <i>JAK2</i> : not only a myeloid issue. <i>Expert Review of Hematology</i> , 2013, 6, 429-439.	1.0	9
392	Telomere shortening in Ph-negative chronic myeloproliferative neoplasms: A biological marker of polycythemia vera and myelofibrosis, regardless of hydroxycarbamide therapy. <i>Experimental Hematology</i> , 2013, 41, 627-634.	0.2	22
393	Role of radiotherapy in patients with early-stage diffuse large B-cell lymphoma of Waldeyer's ring in remission after anthracycline-containing chemotherapy. <i>Leukemia and Lymphoma</i> , 2013, 54, 62-68.	0.6	14
394	Mesenchymal stromal cells and kidney transplantation: pretransplant infusion protects from graft dysfunction while fostering immunoregulation. <i>Transplant International</i> , 2013, 26, 867-878.	0.8	148
395	Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics. <i>MAbs</i> , 2013, 5, 826-837.	2.6	105
396	Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis. <i>Leukemia</i> , 2013, 27, 2084-2086.	3.3	51

#	ARTICLE	IF	CITATIONS
397	<scp>SIE</scp>, <scp>SIES</scp>, <scp>GITMO</scp> revised guidelines for the management of follicular lymphoma. American Journal of Hematology, 2013, 88, 185-192.	2.0	32
398	Impact of Graft-versus-Host Disease Prophylaxis on Outcomes after Myeloablative Single-Unit Umbilical Cord Blood Transplantation. Biology of Blood and Marrow Transplantation, 2013, 19, 1387-1392.	2.0	24
399	The costs of mobilisation and collection of peripheral blood stem cells in multiple myeloma and lymphoma in an European country: Results from The Gruppo Italiano Trapianto Midollo Osseo (GITMO) and Societ� Italiana di Emaferesi e Manipolazione Cellulare (SidEM) survey. Transfusion and Apheresis Science, 2013, 49, 615-622.	0.5	8
400	Are Outcomes After Myeloablative Conditioning Regimen in Double Cord Blood Transplantation (UCBT) Better Than Single UCBT for Adults with Acute Leukemia in Remission?. Biology of Blood and Marrow Transplantation, 2013, 19, S126.	2.0	0
401	Safe and Effective Treatment of Graft Versus Host Disease with Platelet Lysate-Expanded Mesenchymal Stromal Cells: A Prospective, Multicentric, Phase 1 Study. Biology of Blood and Marrow Transplantation, 2013, 19, S135.	2.0	0
402	Givinostat and hydroxyurea synergize in vitro to induce apoptosis of cells from JAK2V617F myeloproliferative neoplasm patients. Experimental Hematology, 2013, 41, 253-260.e2.	0.2	30
403	Allogeneic Hematopoietic Cell Transplantation from Unrelated Donors in Multiple Myeloma: Study from the Italian Bone Marrow Donor Registry. Biology of Blood and Marrow Transplantation, 2013, 19, 940-948.	2.0	20
404	The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT. Bone Marrow Transplantation, 2013, 48, 1409-1414.	1.3	63
405	Should Cyto-reductive Treatment Be Performed Before Transplantation in Patients With High-Risk Myelodysplastic Syndrome?. Journal of Clinical Oncology, 2013, 31, 2761-2762.	0.8	38
406	The lymphocyte to monocyte ratio improves the IPI risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy. American Journal of Hematology, 2013, 88, 1062-1067.	2.0	54
407	Ofatumumab Is More Efficient than Rituximab in Lysing B Chronic Lymphocytic Leukemia Cells in Whole Blood and in Combination with Chemotherapy. Journal of Immunology, 2013, 190, 231-239.	0.4	95
408	Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib. Leukemia, 2013, 27, 1511-1519.	3.3	119
409	The CIBMTR score predicts survival of AML patients undergoing allogeneic transplantation with active disease after a myeloablative or reduced intensity conditioning: a retrospective analysis of the Gruppo Italiano Trapianto Di Midollo Osseo. Leukemia, 2013, 27, 2086-2091.	3.3	37
410	Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia, 2013, 27, 1874-1881.	3.3	540
411	Autologous stem cell transplantation for enteropathy-associated T-cell lymphoma: a retrospective study by the EBMT. Blood, 2013, 121, 2529-2532.	0.6	70
412	Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. Blood, 2013, 122, 3482-3491.	0.6	206
413	High cure rates in Burkitt lymphoma and leukemia: a Northern Italy Leukemia Group study of the German short intensive rituximab-chemotherapy program. Haematologica, 2013, 98, 1718-1725.	1.7	40
414	The Polo-Like Kinase 1 (PLK1) Inhibitor NMS-P937 Is Effective in a New Model of Disseminated Primary CD56+ Acute Monoblastic Leukaemia. PLoS ONE, 2013, 8, e58424.	1.1	31

#	ARTICLE	IF	CITATIONS
415	A Phase 2 Study Of Ruxolitinib In Patients With Splanchnic Vein Thrombosis Associated With Myeloproliferative Neoplasm. Preliminary Results. <i>Blood</i> , 2013, 122, 1583-1583.	0.6	4
416	High-Dose Rituximab In The Conditioning Regimen Before Allogeneic Stem Cell Transplantation Decreases Deaths Related To Gvhd Without Affecting The Anti-Lymphoma Effect. <i>Blood</i> , 2013, 122, 2059-2059.	0.6	2
417	Massive, Clinical Grade Expansion Of Polyclonal T Cells Using Blinatumomab For Adoptive Autologous Cellular Therapy Of CLL Patients. <i>Blood</i> , 2013, 122, 3272-3272.	0.6	1
418	Phase 3 Study Of Pomalidomide In Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis With RBC-Transfusion-Dependence. <i>Blood</i> , 2013, 122, 394-394.	0.6	29
419	Myeloproliferative (MPN) Symptom Burden Response Thresholds: Assessment Of MPN-SAF TSS Quartiles As Potential Markers Of Symptom Response. <i>Blood</i> , 2013, 122, 4067-4067.	0.6	6
420	Cerebral Vein Thrombosis In Patients With Myeloproliferative Neoplasms. <i>Blood</i> , 2013, 122, 4068-4068.	0.6	10
421	Insomnia, Quality Of Life and MPN Symptom Burden: An Analysis By The MPN Quality Of Life International Study Group (MPN-QOL ISG). <i>Blood</i> , 2013, 122, 4087-4087.	0.6	9
422	Sexuality Challenges, Intimacy, and MPN Symptom Burden: An Analysis By The MPN Quality Of Life International Study Group (MPN-QOL ISG). <i>Blood</i> , 2013, 122, 4088-4088.	0.6	6
423	A Phase II Multi-Center Trial Of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) In Older Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients. <i>Blood</i> , 2013, 122, 4177-4177.	0.6	2
424	Long-Term Health Related Quality Of Life and Symptom Burden In Patients With Acute Promyelocytic Leukemia Treated With All-Trans Retinoic Acid (ATRA) and Chemotherapy. <i>Blood</i> , 2013, 122, 770-770.	0.6	2
425	Identification By Gene Expression Profiling Of CIITA-Dependent HLA Class II Transcriptional Downregulation As a Novel Mechanism Of Leukemia Immune Escape and Relapse After Allogeneic HSCT. <i>Blood</i> , 2013, 122, 3748-3748.	0.6	0
426	Increased Platelet Thrombus Formation Under Flow Condition In Myeloproliferative Neoplasms (MPN). <i>Blood</i> , 2013, 122, 33-33.	0.6	3
427	The Long-Term Outcome Of Adult Patients With Acute Myeloid Leukemia NPM+ and FLT3/ITD- Is Not Significantly Improved By The Application Of An Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2013, 122, 2648-2648.	0.6	0
428	Integrative Analysis Of mRNA/miRNA Expression Profiles Identified JARID2 As a Shared Target Of Deregulated Mirnas In Primary Myelofibrosis. <i>Blood</i> , 2013, 122, 1600-1600.	0.6	0
429	Phase II Randomized Trial Of Radiation-Free Central Nervous System (CNS) Prophylaxis Comparing Intrathecal Triple Therapy With Liposomal Cytarabine (DepoCyte®) In Adult Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2013, 122, 3901-3901.	0.6	0
430	Quantitative DNA Real-Time PCR Compared To mRNA and Cytogenetic Assays To Monitor Minimal Residual Disease In Chronic Myeloid Leukemia. <i>Blood</i> , 2013, 122, 1316-1316.	0.6	17
431	Nilotinib For Steroid-Refractory Chronic Graft Versus Host Disease (SR-cGVHD): Preliminary Results Of a Phase I-II GITMO Study (Gruppo Italiano Trapianto di Midollo Osseo). <i>Blood</i> , 2013, 122, 4608-4608.	0.6	0
432	Allogeneic Stem Cell Transplantation For Acute Myeloid Leukemia With Normal Cytogenetics (CN-AML): Outcome, Risk Factors and Role Of Molecular Subgroups In 752 Patients – A Report From The Acute Leukemia Working Party Of EBMT. <i>Blood</i> , 2013, 122, 921-921.	0.6	0

#	ARTICLE	IF	CITATIONS
433	The Revised International Prognostic Scoring System (IPSS-R) Predicts Posttransplantation Outcome Of Patients With Myelodysplastic Syndrome Receiving Allogeneic Stem Cell Transplantation: A Basis For Clinical Decision Making. <i>Blood</i> , 2013, 122, 2765-2765.	0.6	0
434	NK leukemia: a rare case of oral manifestations representing the initial sign. <i>Annali Di Stomatologia</i> , 2013, 4, 28.	0.6	1
435	Mesenchymal Stromal Cells Do Not Increase the Risk of Viral Reactivation Nor the Severity of Viral Events in Recipients of Allogeneic Stem Cell Transplantation. <i>Stem Cells International</i> , 2012, 2012, 1-6.	1.2	28
436	A novel murine model of myeloproliferative disorders generated by overexpression of the transcription factor NF-E2. <i>Journal of Experimental Medicine</i> , 2012, 209, 35-50.	4.2	67
437	Experience with pegylated interferon α -2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients. <i>Haematologica</i> , 2012, 97, 1570-1573.	1.7	79
438	Modern therapy of young and adult Ph-ALL. <i>Leukemia Supplements</i> , 2012, 1, S5-S6.	0.1	2
439	Outcome of patients activating an unrelated donor search: the impact of transplant with reduced intensity conditioning in a large cohort of consecutive high-risk patients. <i>Leukemia</i> , 2012, 26, 1779-1785.	3.3	14
440	Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. <i>Leukemia</i> , 2012, 26, 520-526.	3.3	129
441	Proposed definition of "poor mobilizer"™ in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo Italiano Trapianto di Midollo Osseo. <i>Bone Marrow Transplantation</i> , 2012, 47, 342-351.	1.3	156
442	A novel, highly sensitive and rapid allele-specific loop-mediated amplification assay for the detection of the JAK2V617F mutation in chronic myeloproliferative neoplasms. <i>Haematologica</i> , 2012, 97, 1394-1400.	1.7	21
443	Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs. <i>Journal of Clinical Oncology</i> , 2012, 30, 4098-4103.	0.8	344
444	CD20 expression has no prognostic role in Philadelphia-negative B-precursor acute lymphoblastic leukemia: new insights from the molecular study of minimal residual disease. <i>Haematologica</i> , 2012, 97, 568-571.	1.7	25
445	Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome. <i>Blood</i> , 2012, 119, 2239-2241.	0.6	90
446	Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index: a prospective, multicenter GITMO study. <i>Blood</i> , 2012, 120, 1327-1333.	0.6	99
447	New potential markers of severe thrombo-hemorrhagic syndrome (THS) in acute promyelocytic leukemia (APL) patients: activated FVIIa-antithrombin complex (FVIIa-AT) and Tissue Factor (TF) mRNA. <i>Thrombosis Research</i> , 2012, 129, S159.	0.8	2
448	The HDAC inhibitor Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2V617F myeloproliferative neoplasm cells. <i>Experimental Hematology</i> , 2012, 40, 634-645.e10.	0.2	36
449	Chronic GVHD is associated with inferior relapse risk irrespective of stem cell source among patients receiving transplantation from unrelated donors. <i>Bone Marrow Transplantation</i> , 2012, 47, 1474-1478.	1.3	34
450	High-Dose Therapy and Autologous Stem Cell Transplantation in First Relapse for Diffuse Large B Cell Lymphoma in the Rituximab Era: An Analysis Based On Data from the European Blood and Marrow Transplantation Registry. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 788-793.	2.0	102

#	ARTICLE	IF	CITATIONS
451	Results of Phase II Clinical Trial MPD-RC 101: Allogeneic Hematopoietic Stem Cell Transplantation Conditioned with Fludarabine/Melphalan in Patients with Myelofibrosis. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, S216.	2.0	7
452	Development and validation of an International Prognostic Score of thrombosis in World Health Organizationâ€œessential thrombocythemia (IPSET-thrombosis). <i>Blood</i> , 2012, 120, 5128-5133.	0.6	461
453	Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis. <i>Blood</i> , 2012, 120, 569-571.	0.6	69
454	Rituximab in Idiopathic Membranous Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2012, 23, 1416-1425.	3.0	252
455	p38 γ MAPK interacts with and inhibits RAR α : suppression of the kinase enhances the therapeutic activity of retinoids in acute myeloid leukemia cells. <i>Leukemia</i> , 2012, 26, 1850-1861.	3.3	24
456	Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. <i>Leukemia</i> , 2012, 26, 716-719.	3.3	149
457	Hydroxyureaâ€œrelated toxicity in 3,411 patients with Ph ⁻ â€œnegative MPN. <i>American Journal of Hematology</i> , 2012, 87, 552-554.	2.0	105
458	Mesenchymal stromal cells for the treatment of graft-versus-host disease: understanding the in vivo biological effect through patient immune monitoring. <i>Leukemia</i> , 2012, 26, 1681-1684.	3.3	63
459	Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: A GITMO study. <i>Annals of Hematology</i> , 2012, 91, 931-939.	0.8	74
460	<i>ASXL1</i> mutations in primary and secondary myelofibrosis. <i>British Journal of Haematology</i> , 2012, 156, 404-407.	1.2	17
461	Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia. <i>American Journal of Hematology</i> , 2012, 87, 203-204.	2.0	29
462	Results of a lymphoblastic leukemia-like chemotherapy program with risk-adapted mediastinal irradiation and stem cell transplantation for adult patients with lymphoblastic lymphoma. <i>Annals of Hematology</i> , 2012, 91, 73-82.	0.8	36
463	The Myelofibrosis Symptom Burden (MF-SB): An International Phenotypic Cluster Analysis of 329 Patients. <i>Blood</i> , 2012, 120, 1731-1731.	0.6	2
464	Intensified Chemo-Immunotherapy Including up-Front Autologous or Allogeneic Stem Cell Transplantation (SCT) for Young Patients with Newly Diagnosed Peripheral T-Cell Lymphomas: Final Results of a Phase II Multicenter Prospective Clinical Trial. <i>Blood</i> , 2012, 120, 1984-1984.	0.6	1
465	Early Treatment Intensification in Advanced-Stage High-Risk Hodgkin Lymphoma (HL) Patients, with a Positive FDG-PET Scan After Two ABVD Courses â€œ First Interim Analysis of the GITIL/FIL HD0607 Clinical Trial. <i>Blood</i> , 2012, 120, 550-550.	0.6	8
466	ATRA and Arsenic Trioxide (ATO) Versus ATRA and Idarubicin (AIDA) for Newly Diagnosed, Non High-Risk Acute Promyelocytic Leukemia (APL): Results of the Phase III, Prospective, Randomized, Intergroup APL0406 Study by the Italian-German Cooperative Groups Gimema-SAL-AMLSC. <i>Blood</i> , 2012, 120, 6-6.	0.6	18
467	Chemoimmunotherapy with R-CHOP or High Dose Sequential Therapy with Autologous Stem Cell Transplantation (R-HDS) for High Risk Diffuse Large B-Cell Lymphomas Patients: Results of the Randomized R-HDS0305 Trial by Gruppo Italiano Terapie Innovative Nei Linfomi (GITIL). <i>Blood</i> , 2012, 120, 746-746.	0.6	3
468	Long-Term Efficacy and Safety Results From a Phase II Study of Ruxolitinib in Patients with Polycythemia Vera. <i>Blood</i> , 2012, 120, 804-804.	0.6	6

#	ARTICLE	IF	CITATIONS
469	High Cure Rates in Burkitt Leukemia and Lymphoma: NILG Study of the German Short Intensive Rituximab-Chemotherapy Program. <i>Blood</i> , 2012, 120, 1494-1494.	0.6	0
470	In Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Imatinib (IM) and Chemotherapy in Combination Improve Remission Rate, Stem Cell Transplantation Rate and Long-Term Outcome. <i>Blood</i> , 2012, 120, 662-662.	0.6	1
471	Health-Related Quality of Life in Patients with Primary Immune Thrombocytopenia Compared with the General Population. <i>Blood</i> , 2012, 120, 2056-2056.	0.6	0
472	Early Response Dynamics Including Minimal Residual Disease (MRD) and Adherence to Risk/MRD-Oriented Therapy Are Major Outcome Determinants in Adult Ph-Negative Acute Lymphoblastic Leukemia (ALL).. <i>Blood</i> , 2012, 120, 2573-2573.	0.6	8
473	Lenalidomide in Myelodysplastic Syndromes with 5q Deletion. Results From the Italian National Cancer Registry. <i>Blood</i> , 2012, 120, 3850-3850.	0.6	0
474	In Vivo T Cell Depletion with Antithymocyte Globulin or Alemtuzumab for Unrelated Donor Stem Cell Transplantation with Reduced Intensity Conditioning: Results of a Multicenter Randomized Phase II Clinical Trial (The Global Study) From the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO). <i>Blood</i> , 2012, 120, 221-221.	0.6	0
475	Autologous Stem Cell Transplantation (ASCT) for Enteropathy-Associated T-Cell Lymphoma (EATL): Final Analysis of a Retrospective Study On the Behalf of Lymphoma Working Party (LWP) of the European Group for Blood and Marrow Transplantation (EBMT).. <i>Blood</i> , 2012, 120, 3105-3105.	0.6	0
476	Safe and Effective Treatment of Graft Versus Host Disease with Platelet Lysate-Expanded Human Mesenchymal Stromal Cells: A Phase 1 Study On 47 Adult and Pediatric Patients. <i>Blood</i> , 2012, 120, 743-743.	0.6	2
477	Risk Factors for Overall Survival in Patients with Acute Myeloid Leukemia (AML) with Normal Karyotype Undergoing Allogeneic Stem Cell Transplantation (allo-SCT) in First Complete Remission (CR1): A Report On 366 Patients From the Acute Leukemia Working Party of EBMT. <i>Blood</i> , 2012, 120, 1975-1975.	0.6	5
478	Primary Refractory Disease in Non-Hodgkin's Lymphoma: A Retrospective Study On 3,952 Newly Diagnosed Patients Undergoing First-Line Chemotherapy. <i>Blood</i> , 2012, 120, 305-305.	0.6	0
479	Role of Front-Line High Dose Therapy with Stem Cell Transplant in Peripheral T-Cell Lymphomas. A Single Center Experience.. <i>Blood</i> , 2012, 120, 2733-2733.	0.6	4
480	Essential Thrombocythemia (ET) and Polycythemia Vera (PV) Symptom Burden: Phenotypic Cluster Analysis Among an International Sample of 1,141 ET and PV Patients. <i>Blood</i> , 2012, 120, 1726-1726.	0.6	4
481	The Peripheral Blood Lymphocyte to Monocyte Ratio At Diagnosis Is a Potent Outcome Predictor in Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Long-Term Analysis On 973 Patients Receiving Chemotherapy with or without Rituximab. <i>Blood</i> , 2012, 120, 1553-1553.	0.6	2
482	Validation of the Cibmtr Score in Predicting the Outcome of Hematopoietic Stem-Cell Transplantation in AML Patients Not in Complete Remission At the Time of Conditioning: A Retrospective Analysis On Behalf of the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO). <i>Blood</i> , 2012, 120, 2005-2005.	0.6	0
483	Ultra Rapid, One Step Molecular Detection of BCR-ABL Major and Minor Transcripts by Isothermal RT-Loop Mediated Amplification Reaction.. <i>Blood</i> , 2012, 120, 2515-2515.	0.6	0
484	In Adult Acute Lymphoblastic Leukemia (ALL) Different Minimal Residual Disease (MRD) Levels Predict Clinical Outcome in All Patients and Response to Allogeneic/Autologous Transplantation in MRD-Positive Patients.. <i>Blood</i> , 2012, 120, 2493-2493.	0.6	4
485	Fatigue Is the Major Aspect Compromising Health-Related Quality of Life of Chronic Myeloid Leukemia Patients Receiving Long-Term Imatinib Therapy. <i>Blood</i> , 2012, 120, 4234-4234.	0.6	0
486	Long Telomere Length of White Blood Cells Following Umbilical Cord Blood Transplant (UCBT): Is Hematopoiesis Younger in UCBT Recipients Compared to Healthy Age-Matched Controls?. <i>Blood</i> , 2012, 120, 4094-4094.	0.6	0

#	ARTICLE	IF	CITATIONS
487	Comparison of the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Across Nine Linguistic Translations Among an International Sample of 1,851 Myeloproliferative Neoplasm (MPN) Patients.. Blood, 2012, 120, 2852-2852.	0.6	0
488	Are Outcomes After Myeloablative Conditioning Regimen in Double Cord Blood Transplantation (UCBT) Better Than Single UCBT for Adults with Acute Leukemia in Remission?.. Blood, 2012, 120, 3083-3083.	0.6	0
489	Risk Factors for Thrombosis Among 1,545 Patients with Polycythemia Vera: An International Study.. Blood, 2012, 120, 2849-2849.	0.6	0
490	High response rate and improvement of long-term survival with combined treatment modalities in patients with poor-risk primary thyroid diffuse large B-cell lymphoma: an International Extranodal Lymphoma Study Group and Intergruppo Italiano Linfomi study. Leukemia and Lymphoma, 2011, 52, 823-832.	0.6	23
491	Minimally manipulated whole human umbilical cord is a rich source of clinical-grade human mesenchymal stromal cells expanded in human platelet lysate. Cytotherapy, 2011, 13, 786-801.	0.3	104
492	Autologous Mesenchymal Stromal Cells and Kidney Transplantation. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 412-422.	2.2	273
493	Immunomonitoring of Transplanted Patients Infused With Mesenchymal Stromal Cells (MSC) for Treating Steroid-Refractory GVHD. Biology of Blood and Marrow Transplantation, 2011, 17, S162-S163.	2.0	1
494	Platelet-Lysate-Expanded Mesenchymal Stromal Cells for the Treatment of Resistant GVHD. Biology of Blood and Marrow Transplantation, 2011, 17, S169.	2.0	0
495	Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood, 2011, 118, 4554-4560.	0.6	221
496	Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity. Blood, 2011, 118, 3301-3310.	0.6	188
497	JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients. Blood, 2011, 118, 2599-2601.	0.6	61
498	Enhanced killing of human B-cell lymphoma targets by combined use of cytokine-induced killer cell (CIK) cultures and anti-CD20 antibodies. Blood, 2011, 117, 510-518.	0.6	57
499	AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. Blood, 2011, 117, 4716-4725.	0.6	173
500	The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients. Blood, 2011, 118, 401-408.	0.6	280
501	Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. Blood, 2011, 118, 2069-2076.	0.6	144
502	Mutations of <i>CD79A</i> , <i>CD79B</i> and <i>EZH2</i> genes in immunodeficiency-related non-Hodgkin lymphomas. British Journal of Haematology, 2011, 152, 777-780.	1.2	16
503	Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim PET positive after two ABVD courses. British Journal of Haematology, 2011, 152, 551-560.	1.2	127
504	Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype. Blood, 2011, 118, 6153-6163.	0.6	227

#	ARTICLE	IF	CITATIONS
505	CLIP1: a new prognostic index for indolent cutaneous B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11). <i>Annals of Hematology</i> , 2011, 90, 401-408.	0.8	28
506	Fludarabine, cyclophosphamide, doxorubicin (FCD), and rituximab: A remission induction therapy for aggressive pediatric postâ€transplant lymphoproliferative disease (PTLD). <i>Pediatric Blood and Cancer</i> , 2011, 57, 324-328.	0.8	8
507	Plateletâ€induced thrombin generation by the calibrated automated thrombogram assay is increased in patients with essential thrombocythemia and polycythemia vera. <i>American Journal of Hematology</i> , 2011, 86, 337-342.	2.0	78
508	Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. <i>Haematologica</i> , 2011, 96, 315-318.	1.7	160
509	ABVD versus BEACOPP for Hodgkin's Lymphoma When High-Dose Salvage Is Planned. <i>New England Journal of Medicine</i> , 2011, 365, 203-212.	13.9	379
510	Mechanism of Action of Type II, Glycoengineered, Anti-CD20 Monoclonal Antibody GA101 in B-Chronic Lymphocytic Leukemia Whole Blood Assays in Comparison with Rituximab and Alemtuzumab. <i>Journal of Immunology</i> , 2011, 186, 3762-3769.	0.4	198
511	A randomized comparison of caspofungin versus antifungal prophylaxis according to investigator policy in acute leukaemia patients undergoing induction chemotherapy (PROFIL-C study). <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 2140-2145.	1.3	28
512	Risk Factors for the Development of Secondary Malignancy After High-Dose Chemotherapy and Autograft, With or Without Rituximab: A 20-Year Retrospective Follow-Up Study in Patients With Lymphoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 814-824.	0.8	151
513	Safety, Tolerability and Activity of Ofatumumab, Bendamustine and Dexamethasone Combination As First-Line Treatment of Mantle-Cell Lymphoma in the Elderly: A Multicenter Study. <i>Blood</i> , 2011, 118, 1647-1647.	0.6	8
514	A Phase II Study of the HDAC Inhibitor Givinostat In Combination with Hydroxyurea In Patients with Polycythemia Vera Resistant to Hydroxyurea Monotherapy. <i>Blood</i> , 2011, 118, 1748-1748.	0.6	9
515	Results of Phase II Clinical Trial MPD-RC 101: Allogeneic Hematopoietic Stem Cell Transplantation Conditioned with Fludarabine/Melphalan in Patients with Myelofibrosis. <i>Blood</i> , 2011, 118, 1750-1750.	0.6	2
516	Allogeneic Bone Marrow Transplantation From Unrelated Donors in Multiple Myeloma: A Study from the Italian Bone Marrow Transplantation Donor Registry. <i>Blood</i> , 2011, 118, 2009-2009.	0.6	1
517	Survival and Prognosis Among 1,263 Patients with Polycythemia Vera: An International Study. <i>Blood</i> , 2011, 118, 277-277.	0.6	7
518	The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Derived Total Symptom Score (TSS): An International Trial of 1433 Patients with Myeloproliferative Neoplasms (MPNs). <i>Blood</i> , 2011, 118, 3839-3839.	0.6	4
519	A Phase II Study of Sequential Administration of DLI and Cytokine Induced Killer (CIK) Cells in Patients with Hematologic Malignancies Relapsing After Allogeneic Hematopoietic Stem Cell Transplantation: Preliminary Results. <i>Blood</i> , 2011, 118, 657-657.	0.6	2
520	Symptomatic burden in myelofibrosis (MF): Prospective international assessment in 128 MF patients.. <i>Journal of Clinical Oncology</i> , 2011, 29, 6610-6610.	0.8	4
521	Outcome of Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) for Philadelphia Chromosome Acute Lymphoblastic Leukemia (Ph+ALL) in First Complete Remission (CR1) At the Era of Tyrosine Kinase Inhibitors (TKI): A Survey From the Acute Leukemia Working Party (ALWP) of EBMT. <i>Blood</i> , 2011, 118, 4107-4107.	0.6	0
522	Autologous Stem Cell Transplantation (ASCT) for Enteropathy-Associated T-Cell Lymphoma (EATCL): A Retrospective Study of the European Group for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2011, 118, 3115-3115.	0.6	0

#	ARTICLE	IF	CITATIONS
523	Activated FVII-Antithrombin Complex and Tissue Factor mRNA As Potential Markers of Severe Thrombo-Hemorrhagic Syndrome in APL Patients. <i>Blood</i> , 2011, 118, 1195-1195.	0.6	1
524	Pegylated Interferon Alpha " 2a in Patients with Myeloproliferative Neoplasms (MPN): International Experience in 115 Cases. <i>Blood</i> , 2011, 118, 2818-2818.	0.6	0
525	Intermittent Imatinib (INTERIM) Treatment of Patients with Ph+ Chronic Myeloid Leukemia in Complete Cytogenetic Response: Cytogenetic and Molecular Data At One Year. <i>Blood</i> , 2011, 118, 1682-1682.	0.6	0
526	Decision Analysis of Allogeneic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome Stratified According to the Who Classification-Based Prognostic Scoring System (WPSS). <i>Blood</i> , 2011, 118, 116-116.	0.6	1
527	The Role of Total Body Irradiation (TBI) in the High-Dose Regimen of Patients with Follicular Lymphoma (FL) Treated with Autologous Stem Cell Transplant (ASCT) in the Rituximab Era. A Retrospective Study of the EBMT Lymphoma Working Party. <i>Blood</i> , 2011, 118, 502-502.	0.6	1
528	Sensitivity and Specificity of Laboratory Parameters to Detect Early/Prefibrotic Myelofibrosis in 857 Patients with Essential Thrombocythemia. A Diagnostic Algorithm. <i>Blood</i> , 2011, 118, 5148-5148.	0.6	0
529	Chronic Myeloid Leukemia: Molecular Monitoring of Residual Disease by Genomic DNA Compared to Conventional mRNA Analysis in Follow-Ups up to 8 Years. <i>Blood</i> , 2011, 118, 1687-1687.	0.6	0
530	A 41-Gene Signature Predicts Complete Response (CR) to Bortezomib-Thalidomide-Dexamethasone (VTD) As Induction Therapy Prior to Autologous Stem-Cell Transplantation (ASCT) in Multiple Myeloma (MM). <i>Blood</i> , 2011, 118, 805-805.	0.6	0
531	Whole-Exome Sequencing Identifies Recurrent Mutations of BCOR in Acute Myeloid Leukemia with Normal Karyotype. <i>Blood</i> , 2011, 118, 71-71.	0.6	1
532	Unrelated Cord Blood Transplantation Using Myeloablative Conditioning Regimen for Adults with Acute Myeloid Leukemia in First Complete Remission. A Survey by EUROCORD and the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2011, 118, 836-836.	0.6	0
533	Genomic and Transcriptional Immunoediting of Acute Myeloid Leukemia in Response to Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2011, 118, 329-329.	0.6	0
534	Pleiotropic anti-myeloma activity of ITF2357: inhibition of interleukin-6 receptor signaling and repression of miR-19a and miR-19b. <i>Haematologica</i> , 2010, 95, 260-269.	1.7	36
535	Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study. <i>Haematologica</i> , 2010, 95, 476-484.	1.7	144
536	Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria. <i>Blood</i> , 2010, 116, 1051-1055.	0.6	56
537	Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. <i>Blood</i> , 2010, 116, 3171-3179.	0.6	290
538	Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia. <i>Haematologica</i> , 2010, 95, 1435-1438.	1.7	41
539	A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma. <i>Annals of Hematology</i> , 2010, 89, 185-190.	0.8	99
540	Therapy of myelofibrosis (excluding JAK2 inhibitors). <i>International Journal of Hematology</i> , 2010, 91, 180-188.	0.7	6

#	ARTICLE	IF	CITATIONS
541	Therapeutic efficacy of the pan-cdk inhibitor PHA-793887 in vitro and in vivo in engraftment and high-burden leukemia models. <i>Experimental Hematology</i> , 2010, 38, 259-269.e2.	0.2	12
542	Single nucleotide polymorphism arrays provide new insights in the pathogenesis of post-transplant diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2010, 149, 569-577.	1.2	53
543	A pilot study of the Histone Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. <i>British Journal of Haematology</i> , 2010, 150, 446-455.	1.2	202
544	Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. <i>Leukemia</i> , 2010, 24, 521-535.	3.3	302
545	Chemotherapy-Phased Imatinib Pulses Improve Long-Term Outcome of Adult Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Northern Italy Leukemia Group Protocol 09/00. <i>Journal of Clinical Oncology</i> , 2010, 28, 3644-3652.	0.8	250
546	Hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria: long-term results of a retrospective study on behalf of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). <i>Haematologica</i> , 2010, 95, 983-988.	1.7	64
547	Platelet-lysate-Expanded Mesenchymal Stromal Cells as a Salvage Therapy for Severe Resistant Graft-versus-Host Disease in a Pediatric Population. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1293-1301.	2.0	165
548	Feasibility and Safety of Adoptive Immunotherapy with CIK Cells after Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1603-1607.	2.0	49
549	PO-28 Increased thrombin generation (TG) potential of platelets from myeloproliferative neoplasms. <i>Thrombosis Research</i> , 2010, 125, S173.	0.8	0
550	PO-52 Determination of thrombin generation (TG) and procoagulant activity (PCA) expressed by circulating microparticles (MP) in essential thrombocythemia (ET) patients. <i>Thrombosis Research</i> , 2010, 125, S179-S180.	0.8	0
551	Thrombosis in primary myelofibrosis: incidence and risk factors. <i>Blood</i> , 2010, 115, 778-782.	0.6	216
552	Understanding the Immunomodulatory Effect of Mesenchymal Stem Cell Infused In Transplanted Patients with Steroid-Refractory GvHD. <i>Blood</i> , 2010, 116, 2306-2306.	0.6	3
553	Durable Responses with the JAK1/ JAK2 Inhibitor, INCB018424, In Patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory or Intolerant to Hydroxyurea (HU). <i>Blood</i> , 2010, 116, 313-313.	0.6	33
554	A Phase 1/2 Study of RAD001, a mTOR Inhibitor, In Patients with Myelofibrosis: Final Results. <i>Blood</i> , 2010, 116, 314-314.	0.6	7
555	Improved Clinical Outcome of Adult Patients with Ph+ ALL After a Combined Imatinib-Chemotherapy Induction/Consolidation Program Followed by Allogeneic Hematopoietic Stem Cell Transplantation: Results From a Prospective Study of the Northern Italy Leukemia Group. <i>Blood</i> , 2010, 116, 682-682.	0.6	1
556	Prospective Validation of the Italian Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF: Italian) In 186 MPN Patients. <i>Blood</i> , 2010, 116, 5060-5060.	0.6	7
557	The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): An International Prospective Validation Trial In 402 Patients. <i>Blood</i> , 2010, 116, 4095-4095.	0.6	5
558	Telomere Length In Ph - Negative Chronic Myeloproliferative Neoplasms: It Is Reduced According to JAK2 V617F Mutation Allele Burden and It Is Not Affected by Cyto-reductive Treatment with Hydroxyurea. <i>Blood</i> , 2010, 116, 1975-1975.	0.6	1

#	ARTICLE	IF	CITATIONS
559	ADP-Induced Whole Blood Aggregometry and Platelet-Associated Thrombin Generation (TG) In Essential Thrombocythemia (ET) and Polycythemia Vera (PV) Patients. <i>Blood</i> , 2010, 116, 1981-1981.	0.6	2
560	Interim-PET Scan Interpretation In the Ongoing Prospective Clinical Trial HD 0607, In Advanced-Stage Hodgkin Lymphoma: Results of the the Expert Panel Review. <i>Blood</i> , 2010, 116, 3891-3891.	0.6	0
561	Pediatric-Type Therapy Including Lineage-Targeted Methotrexate to Improve Early Minimal Residual Disease Response and Survival In Adult Acute Lymphoblastic Leukemia (ALL): Interim Analysis of Northern Italy Leukemia Group Study 10/07. <i>Blood</i> , 2010, 116, 2131-2131.	0.6	1
562	The HDAC INHIBITOR ITF2357 MODULATES KEY HEMATOPOIETIC GENES in JAK2V617F CELLS From MYELOPROLIFERATIVE Neoplasm PATIENTS. <i>Blood</i> , 2010, 116, 797-797.	0.6	1
563	Enhanced Killing of Human B Lymphoma Targets by Combined Use of Cytokine Induced Killer (CIK) Cultures and Anti-CD20 Antibodies. <i>Blood</i> , 2010, 116, 4285-4285.	0.6	0
564	One Year of Intermittent Imatinib (IM) Treatment (InterIM) Maintains the Complete Cytogenetic Response (CCgR) Previously Achieved with Standard IM Therapy In Elderly (≥ 65 years) Ph+ CML Patients â€“ EudraCT Number 2007â€“005102-42, ClinicalTrials.Gov NCT 00858806.. <i>Blood</i> , 2010, 116, 3412-3412.	0.6	0
565	Health-Related Quality of Life In Patients with Chronic Myeloid Leukemia Undergoing First Line Treatment with Imatinib for at Least Three Years Compared with the General Population. A Multicenter Study Including 448 Patients. <i>Blood</i> , 2010, 116, 2273-2273.	0.6	0
566	Microparticle-Associated Thrombin Generation and Procoagulant Activity Is Increased In Patients with Essential Thrombocythemia. <i>Blood</i> , 2010, 116, 1985-1985.	0.6	1
567	Inhibition of the Peptidyl-Prolyl-Isomerase Pin1 Enhances the Responses of Acute Myeloid Leukemia Cells to Retinoic Acid via Stabilization of RAR α and PML-RAR α . <i>Cancer Research</i> , 2009, 69, 1016-1026.	0.4	57
568	Prophylaxis and Treatment of Invasive Fungal Diseases in Allogeneic Stem Cell Transplantation: Results of a Consensus Process by Gruppo Italiano Trapianto di Midollo Osseo (GITMO). <i>Clinical Infectious Diseases</i> , 2009, 49, 1226-1236.	2.9	51
569	Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives. <i>Journal of Cellular and Molecular Medicine</i> , 2009, 13, 1437-1450.	1.6	23
570	JAK2V617F allele burden and thrombosis: A direct comparison in essential thrombocythemia and polycythemia vera. <i>Experimental Hematology</i> , 2009, 37, 1016-1021.	0.2	89
571	A short low-dose imatinib trial allows rapid identification of responsive patients in hypereosinophilic syndromes. <i>British Journal of Haematology</i> , 2009, 147, 681-685.	1.2	8
572	High-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting in mantle cell lymphoma: a 10-year update of the R-HDS regimen. <i>Bone Marrow Transplantation</i> , 2009, 43, 509-511.	1.3	25
573	HLA matching affects clinical outcome of adult patients undergoing haematopoietic SCT from unrelated donors: a study from the Gruppo Italiano Trapianto di Midollo Osseo and Italian Bone Marrow Donor Registry. <i>Bone Marrow Transplantation</i> , 2009, 44, 571-577.	1.3	48
574	Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). <i>Blood</i> , 2009, 113, 4153-4162.	0.6	387
575	The washouts of discarded bone marrow collection bags and filters are a very abundant source of hMSCs. <i>Cytotherapy</i> , 2009, 11, 403-413.	0.3	30
576	Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. <i>Blood</i> , 2009, 114, 1477-1483.	0.6	196

#	ARTICLE	IF	CITATIONS
577	Molecular Monitoring of Residual Disease in Chronic Myeloid Leukemia by Genomic DNA Compared with Conventional mRNA Analysis. <i>Journal of Molecular Diagnostics</i> , 2009, 11, 482-487.	1.2	29
578	Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo. <i>Blood</i> , 2009, 113, 3375-3382.	0.6	92
579	Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor?. <i>Blood</i> , 2009, 114, 759-763.	0.6	137
580	Toward MSC in Solid Organ Transplantation: 2008 Position Paper of the MISOT Study Group. <i>Transplantation</i> , 2009, 88, 614-619.	0.5	64
581	Hematopoietic Progenitor Cells From Patients with Chronic Mountain Sickness Lack the JAK2V617F Mutation, Show Hypersensitivity to Erythropoietin and Are Inhibited by Statins.. <i>Blood</i> , 2009, 114, 1894-1894.	0.6	3
582	Thrombosis in Primary Myelofibrosis: Incidence and Risk Factors.. <i>Blood</i> , 2009, 114, 2915-2915.	0.6	1
583	RAD001, An Inhibitor of mTOR, Shows Clinical Activity in a Phase I/II Study in Patients with Primary Myelofibrosis (PMF) and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis (PPV/PET) Tj ETQq1 1 0.784314 rgBT /Over	0.6	0
584	A Phase 2 Study of INCB018424, An Oral, Selective JAK1/JAK2 Inhibitor, in Patients with Advanced Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory to Hydroxyurea.. <i>Blood</i> , 2009, 114, 311-311.	0.6	29
585	Predominant Complement Mediated Lysis of B-CLL Cells by Therapeutic MAbs Rituximab and Campath-1H in Whole Blood Assays.. <i>Blood</i> , 2009, 114, 3445-3445.	0.6	1
586	Phase II Multicentric Explorative Study of Intermittent Imatinib (IM) Treatment (INTERIM) in Elderly Patients with Ph+ Chronic Myeloid Leukemia (CML) Who Achieved a Stable Complete Cytogenetic Response (CCgR) with Standard IM Therapy.. <i>Blood</i> , 2009, 114, 860-860.	0.6	3
587	A Recent Update of Three Consecutive Prospective Trials with High-Dose Therapy and Autograft, without or with Rituximab, as Primary Treatment for Advanced-Stage Follicular Lymphoma (FL) Shows a Sizeable Group of Patients Surviving in Continuous Complete Remission up to 16 Years After the End of Treatment: Should We Still Consider FL An Incurable Disease ?.. <i>Blood</i> , 2009, 114, 882-882.	0.6	2
588	Allogeneic Stem Cell Transplantation (Allo-SCT) Following a Reduced-Intensity Conditioning (RIC) Regimen in Relapsed Peripheral T-Cell Lymphomas (PTCL): Results at 4 Year of Median Follow-up.. <i>Blood</i> , 2009, 114, 875-875.	0.6	0
589	Imatinib Long Term Effects (ILTE) Study: An International Study to Evaluate Long-Term Effects in CML Patients.. <i>Blood</i> , 2009, 114, 2199-2199.	0.6	0
590	High-Sensitivity C-Reactive Protein (hs-CRP) and Pentraxin 3 (PTX3) Are Increased in Essential Thrombocythemia and Polycythemia Vera.. <i>Blood</i> , 2009, 114, 1911-1911.	0.6	0
591	Comparison of Outcomes After Allogeneic HSCT for Adult Patients with AML in Remission Using in the Conditioning Regimen Either I.V. Busulfex (BU) Plus Cyclophosphamide (Cy) or TBI Plus Cy: An-ALWP-EBMT Survey.. <i>Blood</i> , 2009, 114, 195-195.	0.6	2
592	Short Chemotherapy-Phased Imatinib (IM) Pulses Improve Long-Term Outcome of Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL).. <i>Blood</i> , 2009, 114, 2029-2029.	0.6	0
593	Changes of JAK2 V617F Allele Burden Over Time in Patients with Polycythemia Vera or Essential Thrombocythemia: A Retrospective Study of 172 Patients.. <i>Blood</i> , 2009, 114, 1892-1892.	0.6	0
594	High Response Rate with Favorable Survival Projections in High-Risk Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Receiving R-CHOP-14 or Early Intensified Chemotherapy with Rituximab and Autograft (R-HDS): Results of the Interim Analysis of A GITIL Prospective Multicenter Phase III Study.. <i>Blood</i> , 2009, 114, 1220-1220.	0.6	0

#	ARTICLE	IF	CITATIONS
595	Male Gender, Quality of Grafted Cells, Advanced Age, Rituximab and Radiotherapy Are the Main Factors That Variously Influence the Occurrence of Secondary Malignancies Following High-Dose Therapy and Autograft: A GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) Survey in 1,347 Lymphoma Patients.. Blood, 2009, 114, 519-519.	0.6	0
596	Correlation of Novel Molecular Markers in Patients with Myeloproliferative Neoplasms.. Blood, 2009, 114, 4968-4968.	0.6	2
597	Cytokine Induced Killer Cells Can Kill Target through Antigen/TCR Dependent and Independent Mechanisms: New Clinical Perspectives of Utilisation.. Blood, 2009, 114, 3024-3024.	0.6	5
598	Caspofungin Primary Antifungal Prophylaxis in Acute Leukemia Patients During Induction Therapy: Results of a Prospective Phase II Multicentric Study (ProfilC Study).. Blood, 2009, 114, 1638-1638.	0.6	0
599	A Novel, Highly Sensitive, Rapid, Non-PCR Based Method for the Detection of the JAK2 V617F Mutation in Chronic Myeloproliferative Neoplasms.. Blood, 2009, 114, 3892-3892.	0.6	0
600	Microhomologies and interspersed repeat elements at genomic breakpoints in chronic myeloid leukemia. Genes Chromosomes and Cancer, 2008, 47, 625-632.	1.5	45
601	Treosulfan/fludarabine as an allogeneic hematopoietic stem cell transplant conditioning regimen for high-risk patients. American Journal of Hematology, 2008, 83, 717-720.	2.0	22
602	Human Bone Marrow Mesenchymal Stem Cells Accelerate Recovery of Acute Renal Injury and Prolong Survival in Mice. Stem Cells, 2008, 26, 2075-2082.	1.4	351
603	The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2V617F. Leukemia, 2008, 22, 740-747.	3.3	141
604	Systematic review: glucocorticosteroids for alcoholic hepatitis – a Cochrane Hepato-Biliary Group systematic review with meta-analyses and trial sequential analyses of randomized clinical trials. Alimentary Pharmacology and Therapeutics, 2008, 27, 1167-1178.	1.9	184
605	16: Long-Term Results of a Gito Retrospective Study on Hematopoietic Stem Cell Transplantation (HSCT) for Paroxysmal Nocturnal Hemoglobinuria (PNH). Biology of Blood and Marrow Transplantation, 2008, 14, 8.	2.0	1
606	925 GLUCOCORTICOSTEROIDS FOR ALCOHOLIC HEPATITIS. Journal of Hepatology, 2008, 48, S347.	1.8	0
607	Rituximab Improves the Efficacy of High-Dose Chemotherapy With Autograft for High-Risk Follicular and Diffuse Large B-Cell Lymphoma: A Multicenter Gruppo Italiano Terapie Innovative nei Linfomi Survey. Journal of Clinical Oncology, 2008, 26, 3166-3175.	0.8	68
608	Reduced intensity conditioning allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Haematologica, 2008, 93, 303-306.	1.7	102
609	Treatment of primary effusion lymphoma with highly active antiviral therapy in the setting of HIV infection. Aids, 2008, 22, 1236-1237.	1.0	30
610	From Palliation to Epigenetic Therapy in Myelofibrosis. Hematology American Society of Hematology Education Program, 2008, 2008, 83-91.	0.9	13
611	Leukocytosis and Risk Stratification Assessment in Essential Thrombocythemia. Journal of Clinical Oncology, 2008, 26, 2732-2736.	0.8	169
612	Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. Blood, 2008, 112, 844-847.	0.6	216

#	ARTICLE	IF	CITATIONS
613	WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). <i>Blood</i> , 2008, 112, 895-902.	0.6	192
614	Prospective, multicenter randomized GITMO/III trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. <i>Blood</i> , 2008, 111, 4004-4013.	0.6	243
615	Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia. <i>Blood</i> , 2008, 112, 3135-3137.	0.6	100
616	Autologous stem cell transplantation in elderly patients (>=60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry. <i>Haematologica</i> , 2008, 93, 1837-1842.	1.7	90
617	A Phase 2A study of the Histone-Deacetylase Inhibitor ITF2357 in Patients with Jak2V617F Positive Chronic Myeloproliferative Neoplasms. <i>Blood</i> , 2008, 112, 100-100.	0.6	28
618	Imatinib Long Term Effects (ILTE) Study: An Independent, International Study in CML Patients.. <i>Blood</i> , 2008, 112, 1099-1099.	0.6	2
619	High Dose Therapy and Autologous Stem Cell Transplantation Still Improves Progression Free Survival in First Relapse for DLBCL in the Rituximab Era: A Study Using Patients as Their Own Controls.. <i>Blood</i> , 2008, 112, 2191-2191.	0.6	1
620	Long-Term Follow-up of Patients Affected by Relapsed Lymphomas Receiving Reduced-Intensity Conditioning (RIC) Regimen Followed by Allogeneic Stem Cell Transplantation (Allo-SCT): An Update of the Phase II Study of the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO). <i>Blood</i> , 2008, 112, 3303-3303.	0.6	26
621	Outcome of Adult AML at First Relapse Following a Risk-Oriented Strategy: An Update of the Northern Italy Leukemia Group (NILG) Experience. <i>Blood</i> , 2008, 112, 4385-4385.	0.6	1
622	Comparable 3-year outcome following ABVD or BEACOPP first-line chemotherapy, plus pre-planned high-dose salvage, in advanced Hodgkin lymphoma (HL): A randomized trial of the Michelangelo, GITIL and ILL cooperative groups. <i>Journal of Clinical Oncology</i> , 2008, 26, 8506-8506.	0.8	21
623	Use of PCR for BCL2/IgH + cells in stage I/II follicular lymphoma to identify positive cells in bone marrow and peripheral blood that can be cleared by lymph-node irradiation. <i>Journal of Clinical Oncology</i> , 2008, 26, 8571-8571.	0.8	0
624	BEACOPP Chemotherapy Is Able to Induce Durable Complete Remission in Poor-Prognosis Hodgkin's Lymphoma Patients with a Positive Interim PET after 2 ABVD Cycles. <i>Blood</i> , 2008, 112, 2594-2594.	0.6	0
625	The Impact of Therapeutic Management and Prognostic Factors on the Outcome of Primary Cutaneous B-Cell Lymphomas (PCBCL) (IELSG 11 Study). <i>Blood</i> , 2008, 112, 3608-3608.	0.6	0
626	Impact of V617F JAK2 Mutation on Monocyte Tissue Factor and Procoagulant Activity in Patients with Essential Thrombocythemia(ET) or Polycythemia VERA (PV). <i>Blood</i> , 2008, 112, 3736-3736.	0.6	0
627	Clinical Relevance of JAK2V617F Allele Burden in Primary and Post-Polycythemic/Post-Thrombocythemic Myelofibrosis. <i>Blood</i> , 2008, 112, 2799-2799.	0.6	0
628	Human Mesenchymal Stroma Cells (hMSCs) Expanded with Human Platelets Lysate Are Safe and Effective For the Treatment of Graft Versus Host Disease. <i>Blood</i> , 2008, 112, 1171-1171.	0.6	1
629	Similar Rate of Thrombosis in Essential Thrombocythemia and Polycythemia Vera Patients after Stratification for JAK2 V617F Allele Burden.. <i>Blood</i> , 2008, 112, 1745-1745.	0.6	0
630	Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases. <i>The Cochrane Library</i> , 2007, , CD003620.	1.5	43

#	ARTICLE	IF	CITATIONS
631	Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study. <i>Haematologica</i> , 2007, 92, 952-959.	1.7	165
632	Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia. <i>Haematologica</i> , 2007, 92, 612-618.	1.7	128
633	Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. <i>Blood</i> , 2007, 109, 2310-2313.	0.6	295
634	Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. <i>Blood</i> , 2007, 110, 840-846.	0.6	419
635	JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. <i>Blood</i> , 2007, 110, 4030-4036.	0.6	233
636	Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status. <i>Haematologica</i> , 2007, 92, 135-136.	1.7	130
637	FcγRIIIA and FcγRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab. <i>Haematologica</i> , 2007, 92, 1127-1130.	1.7	89
638	Nonmyeloablative allogeneic stem cell transplantation in elderly patients with hematological malignancies: Results from the GITMO (Gruppo Italiano Trapianto Midollo Osseo) multicenter prospective clinical trial. <i>American Journal of Hematology</i> , 2007, 82, 863-866.	2.0	22
639	P010 Incidence and risk factors of secondary myelodysplastic syndrome/acute leukemia occurrence following peripheral blood progenitor cell autograft: a GITIL (Gruppo Italiano Terapie Innovative Nei)	1.0	14
640	Expansion of B cell precursors after unrelated cord blood transplantation for an adult patient. <i>Bone Marrow Transplantation</i> , 2007, 40, 283-285.	1.3	6
641	Human platelet lysate allows expansion and clinical grade production of mesenchymal stromal cells from small samples of bone marrow aspirates or marrow filter washouts. <i>Bone Marrow Transplantation</i> , 2007, 40, 785-791.	1.3	148
642	Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. <i>Leukemia</i> , 2007, 21, 2316-2323.	3.3	142
643	Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden. <i>Leukemia</i> , 2007, 21, 1952-1959.	3.3	328
644	The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells. <i>Leukemia</i> , 2007, 21, 1892-1900.	3.3	102
645	Stage I/II follicular lymphoma: spread of bcl-2/IgH+ cells in blood and bone marrow from primary site of disease and possibility of clearance after involved field radiotherapy. <i>British Journal of Haematology</i> , 2007, 137, 216-220.	1.2	20
646	Extracorporeal Photochemotherapy for the Treatment of Chronic Graft-Versus-Host Disease: Trend for a Possible Cell Dose-Related Effect?. <i>Therapeutic Apheresis and Dialysis</i> , 2007, 11, 85-93.	0.4	61
647	A Phase II Multiple Dose Clinical Trial of Histone Deacetylase Inhibitor ITF2357 in Patients with Relapsed or Progressive Multiple Myeloma: Preliminary Results.. <i>Blood</i> , 2007, 110, 1175-1175.	0.6	10
648	Update of a GITIL Cohort Study: Frontline High Dose Sequential Chemotherapy with Rituximab and Autologous Stem Cell Transplantation Induces a High Rate of Long-Term Remissions in Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2007, 110, 1282-1282.	0.6	3

#	ARTICLE	IF	CITATIONS
649	WHO Classification and WPSS Score Predict Post-Transplant Outcome in Adults with Myelodysplastic Syndrome: A Retrospective Study by GITMO - Gruppo Italiano Trapianto Midollo Osseo.. Blood, 2007, 110, 1466-1466.	0.6	3
650	Long-Term Follow-Up of the Randomized GITMO/IIL Trial Comparing CHOP-Rituximab vs. High-Dose Therapy with Rituximab (R-HDS) in High Risk Follicular Lymphoma (FL): Updated Results Suggest the Use of R-HDS as Salvage Treatment.. Blood, 2007, 110, 20-20.	0.6	1
651	The Impact of Allogeneic Hematopoietic Stem Cell Transplantation in Children and Adolescents with Recurring Hodgkin's Lymphoma: An EBMT Study on 151 Patients.. Blood, 2007, 110, 3061-3061.	0.6	1
652	Selective Targeting of the JAK2V617F Mutation in Polycythemia Vera and Essential Thrombocythemia by ITF2357, a Novel Histone Deacetylase Inhibitor.. Blood, 2007, 110, 555-555.	0.6	3
653	The Clinical Phenotype of Patients with Essential Thrombocythemia Harboring MPL 515W>L/K Mutation.. Blood, 2007, 110, 678-678.	0.6	15
654	Prospective, multicenter, randomized GITMO-IIL trial comparing intensive (R-HDS) to conventional chemoimmunotherapy (CHOP-R) in high-risk follicular lymphoma (FL) at diagnosis. Journal of Clinical Oncology, 2007, 25, 8006-8006.	0.8	1
655	A Prospective Phase II Study on Tandem Autografting-Nonmyeloablative Allografting for Newly Diagnosed Myeloma: Final Results of the Gruppo Italiano Trapianto Midollo Osseo.. Blood, 2007, 110, 3026-3026.	0.6	0
656	Efficacy of High-Dose Sequential Chemotherapy and Autograft for Transformed Non Hodgkin's B Cell Lymphoma: Results of a Retrospective Analysis from GITIL (Gruppo Italiano Terapie Innovative nei Tj ETQq0 0 0 rgB0.0 Overlook 10 Tf 50	0.6	0
657	Minimal Residual Disease (MRD)-Oriented Therapy of Adult Acute Lymphoblastic Leukemia (ALL): Final Results of Northern Italy Leukemia Group Study 09/00.. Blood, 2007, 110, 3497-3497.	0.6	0
658	High-Dose Sequential Chemotherapy (HDS) Followed by Autologous Stem Cell Transplantation (ASCT) in Relapsing/Refractory Hodgkin Lymphoma (HL): Long-Term Results.. Blood, 2007, 110, 5118-5118.	0.6	0
659	Primary Thyroid Lymphoma: A Retrospective IELSG and IIL Analysis of Clinical Characteristics, Prognostic Factors, Treatment Outcome and Somatic Hypermutation for Localized Diffuse Large B-Cell Lymphoma (DLBCL).. Blood, 2007, 110, 3432-3432.	0.6	0
660	A Phase I Study of the Proteasome Inhibitor Bortezomib in Patients with Myelofibrosis.. Blood, 2007, 110, 3540-3540.	0.6	39
661	Effect of HLA-Matching on Outcome of Hematopoietic Stem Cell Transplantation from Unrelated Donors: A IBMDR-GITMO Study.. Blood, 2007, 110, 3052-3052.	0.6	0
662	A GITIL Prospective Randomized Multicenter Phase III Study of High Dose Sequential Chemotherapy with Rituximab (R-HDS) and Autologous Transplantation (ASCT) of Peripheral Blood Stem Cells Versus CHOP and Rituximab Delivered Every 14 Days (R-CHOP-14) in High-Risk Patients with Diffuse Large B-Cell Lymphomas (DLBCL): Interim Analysis on Feasibility and Toxicity (Protocol R-HDS 0305).. Blood, 2007, 110, 1898-1898.	0.6	1
663	Autologous Stem Cell Transplantation (ASCT) for Elderly Patients (>= 60 Years) with Non-Hodgkin's Lymphoma (NHL): An Analysis Based on EBMT Registry.. Blood, 2007, 110, 1888-1888.	0.6	0
664	The Risk of Secondary Myelodysplastic Syndrome/Acute Leukemia Following Intensive Therapy and Autograft Correlates with the Type of Cells Grafted: A Survey on 1,347 Lymphoma Patients Receiving the High-Dose Sequential (HDS) Program.. Blood, 2007, 110, 1083-1083.	0.6	0
665	Hyperchidam Verona897 Regimen Is Effective in Treatment of Advanced Peripheral T Cell Lymphoma (PTCL): The GITIL Experience in 33 Cases.. Blood, 2007, 110, 4465-4465.	0.6	0
666	Leukocytosis and Risk Stratification Assessment in Essential Thrombocythemia.. Blood, 2007, 110, 681-681.	0.6	0

#	ARTICLE	IF	CITATIONS
667	S-adenosyl-L-methionine for alcoholic liver diseases. , 2006, , CD002235.		70
668	Anabolic-androgenic steroids for alcoholic liver disease. The Cochrane Library, 2006, , CD003045.	1.5	24
669	Rapid and massive expansion of cord blood-derived cytokine-induced killer cells: an innovative proposal for the treatment of leukemia relapse after cord blood transplantation. Bone Marrow Transplantation, 2006, 38, 621-627.	1.3	80
670	Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia, 2006, 20, 1533-1538.	3.3	235
671	Clinical grade expansion of CD45RA, CD45RO, and CD62L-positive T-cell lines from HLA-compatible donors: High cytotoxic potential against AML and ALL cells. Experimental Hematology, 2006, 34, 475-485.	0.2	15
672	Analysis of immunoglobulin heavy and light chain variable genes in post-transplant lymphoproliferative disorders. Hematological Oncology, 2006, 24, 212-219.	0.8	19
673	Results of Genoidentical Hemopoietic Stem Cell Transplantation With Reduced Intensity Conditioning for Acute Myelocytic Leukemia: Higher Doses of Stem Cells Infused Benefit Patients Receiving Transplants in Second Remission or Beyondâ€”The Acute Leukemia Working Party of the European Cooperative Group for Blood and Marrow Transplantation. Journal of Clinical Oncology, 2006, 24, 3858-3866.	0.8	46
674	Benefit of Rituximab Addition to High-Dose Programs with Autograft for B-Cell Lymphoma: A Multicenter GITIL Survey on 957 Patients.. Blood, 2006, 108, 207-207.	0.6	3
675	Frontline High Dose Sequential Chemotherapy with Rituximab (R-HDS) and Autologous Stem Cell Transplantation Induces High Rates of Complete Response and Prolongs Survival in Mantle Cell Lymphoma (MCL).. Blood, 2006, 108, 3045-3045.	0.6	13
676	Clinical and Molecular Results of the Multicenter Randomized GITMO-IIL Trial in Poor Risk Follicular Lymphoma (FL) at Diagnosis: Rituximab-Supplemented High-Dose Sequential Chemotherapy (R-HDS) Is Superior to CHOP-R in Molecular Remissions Rate, EFS and PFS.. Blood, 2006, 108, 325-325.	0.6	2
677	Incidence of Secondary Myelodysplastic Syndrome/Acute Leukemia in 1,266 Lymphoma Patients Following High-Dose Therapy and Autograft: A Study from GITIL (Gruppo Italiano Terapie Innovative nei Tj ETQq1 106784314rgBT /O		
678	Infusion of Donor Derived Cytokine Induced Killer Cells May Induce Clinical Remission with Limited GVHD in Patients Relapsing after Allogeneic Stem Cell Transplantation.. Blood, 2006, 108, 3698-3698.	0.6	1
679	Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation Represents a Feasible and Effective Treatment Strategy for Advanced Mycosis Fungoides and Sezary Syndrome.. Blood, 2006, 108, 2997-2997.	0.6	0
680	Clinical Significance of JAK2V617F Homozygosity in the Chronic Myeloproliferative Disorders. A Study on 1306 Patients.. Blood, 2006, 108, 664-664.	0.6	3
681	Favorable Influence of Rituximab with High Dose Sequential Chemotherapy (R-HDS) Programs and Autologous Stem Cell Transplantation (ASCT) in Salvage Treatment for Patients with Refractory or Relapsed B-Cell Non-Hodgkinâ€™s Lymphoma.. Blood, 2006, 108, 2744-2744.	0.6	0
682	Potent Inhibition of EEC Colony Formation in JAK2V617F PV and ET by Low Doses of ITF2357, a New Histone Deacetylase Inhibitor.. Blood, 2006, 108, 2702-2702.	0.6	0
683	Rapid and Massive Expansion of Cord Blood Derived Cytokine Induced Killer (CIK) Cells: An Innovative Proposal for the Treatment of Leukemia Relapse after Cord Blood Transplantation.. Blood, 2006, 108, 723-723.	0.6	0
684	Treosulfan - Fludarabine as Ablative Conditioning Regimen for Patients with High Risk Hematologic Malignancies.. Blood, 2006, 108, 5248-5248.	0.6	0

#	ARTICLE	IF	CITATIONS
685	Prolonged Survival of Lymphoma Patients Achieving Complete Remission Following High-Dose Sequential Chemotherapy and Autograft (HDS Program): A GITIL (Gruppo Italiano Terapie Innovative Nei Tj ETQq1 0.0.784314 rgBT / Ov	0.6	14
686	Outcome of Adult AML at First Relapse Following a Risk-Oriented Strategy: The Northern Italy Leukemia Group (NILG) Experience.. Blood, 2006, 108, 5380-5380.	0.6	0
687	Management of nodal diffuse large B-cell lymphomas: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica, 2006, 91, 96-103.	1.7	30
688	The sensitivity of acute lymphoblastic leukemia cells carrying the t(12;21) translocation to campath-1H-mediated cell lysis. Haematologica, 2006, 91, 322-30.	1.7	21
689	Propylthiouracil for alcoholic liver disease. , 2005, , CD002800.		12
690	Colchicine for alcoholic and non-alcoholic liver fibrosis and cirrhosis. The Cochrane Library, 2005, , CD002148.	1.5	44
691	Quantitative PCR of bone marrow BCL2/IgH+ cells at diagnosis predicts treatment response and long-term outcome in follicular non-Hodgkin lymphoma. Blood, 2005, 105, 3428-3433.	0.6	102
692	Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood, 2005, 106, 2969-2976.	0.6	163
693	Gemtuzumab ozogamicin (Mylotarg) has therapeutic activity against CD33+ acute lymphoblastic leukaemias in vitro and in vivo. British Journal of Haematology, 2005, 128, 310-317.	1.2	52
694	Effect of Age and Previous Autologous Transplantation on Nonrelapse Mortality and Survival in Patients Treated With Reduced-Intensity Conditioning and Allografting for Advanced Hematologic Malignancies. Journal of Clinical Oncology, 2005, 23, 6690-6698.	0.8	58
695	Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases. , 2005, , CD003620.		20
696	Reduced-Intensity Conditioning Followed by Allogeneic Stem Cell Transplantation (allo-SCT) Is an Effective Salvage Treatment for Peripheral T-Cell Non-Hodgkinâ€™s Lymphoma (PTCL).. Blood, 2005, 106, 1128-1128.	0.6	2
697	Low Prevalence of JAK2 Val617Phe Mutation in Patients with Idiopathic Erythrocytosis.. Blood, 2005, 106, 2581-2581.	0.6	3
698	Unrelated Hematopoietic Stem Cell Transplantation with Reduced Intensity Regimens in High Risk Patients for Age or Disease: Results from Two Independent Prospective GITMO Studies.. Blood, 2005, 106, 2888-2888.	0.6	1
699	Distinct Hemostatic Profile of Leukocytes in Essential Thrombocythemia (ET) Carrying the JAK2 V617F Mutation.. Blood, 2005, 106, 378-378.	0.6	7
700	Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) for Patients with Acute Lymphoblastic Leukemia (ALL): A Survey from the European Group for Blood and Marrow Transplantation (EBMT).. Blood, 2005, 106, 659-659.	0.6	5
701	Rituximab-Supplemented High-Dose Sequential Chemotherapy (HDS) Has Superior Response Rate and Event-Free Survival (EFS) Compared to R-CHOP in Poor Risk Follicular Lymphoma (FL) at Diagnosis: Results from a Multicenter Randomized GITMO Trial.. Blood, 2005, 106, 675-675.	0.6	3
702	Acute Lymphoblastic Leukaemia Cells Carrying the t(12;21) Translocation Are Highly Sensitive to Alemtuzumab Mediated Cell Lysis.. Blood, 2005, 106, 872-872.	0.6	4

#	ARTICLE	IF	CITATIONS
703	Bone Marrow BCL2/IgH+ Cells at Diagnosis and Not FCGR3A Polymorphism Predict Response in Follicular Non-Hodgkin's Lymphoma Patients Treated with Sequential CHOP and Rituximab.. Blood, 2005, 106, 985-985.	0.6	1
704	Minimal Residual Disease (MRD) and Risk-Oriented Therapy in Adult Acute Lymphoblastic Leukemia (ALL).. Blood, 2005, 106, 1836-1836.	0.6	1
705	Time- and Dose-Response Relationships of Imatinib Mesylate (Glivec) Therapy for Chronic Hypereosinophilic Syndromes.. Blood, 2005, 106, 2596-2596.	0.6	0
706	The Stage-Modified IPI (MIPI), Histology and a Combined Treatment Influence the Clinical Outcome of 401 Patients with Primary Extranodal Head and Neck B-Cell Lymphomas (PHNBCL) (IELSG 23).. Blood, 2005, 106, 927-927.	0.6	1
707	JAK2 Val617Phe Mutation Correlates with the Risk of Thrombosis in Patients with Essential Thrombocythemia.. Blood, 2005, 106, 2580-2580.	0.6	15
708	Potent Cytotoxicity Against Multiple Myeloma and Acute Myeloid Leukemia Cells by a New Histone Deacetylase Inhibitor ITF2357.. Blood, 2005, 106, 3361-3361.	0.6	0
709	The Addition of Rituximab to High Dose Sequential Chemotherapy (HDS) Programs with Autologous Transplantation Significantly Improves the Outcome of Patients with Refractory or Relapsed B-Cell Non Hodgkin's Lymphoma.. Blood, 2005, 106, 2084-2084.	0.6	0
710	Management of nodal indolent (non marginal-zone) non-Hodgkin's lymphomas: practice guidelines from the Italian Society of Hematology, Italian Society of Experimental Hematology and Italian Group for Bone Marrow Transplantation. Haematologica, 2005, 90, 1236-57.	1.7	30
711	Feasibility and outcome of tandem stem cell autotransplants in multiple myeloma. Haematologica, 2005, 90, 1643-9.	1.7	11
712	Characterization of CD20-Transduced T Lymphocytes as an Alternative Suicide Gene Therapy Approach for the Treatment of Graft-Versus-Host Disease. Human Gene Therapy, 2004, 15, 63-76.	1.4	94
713	Graft-Versus-Lymphoma Effect in Relapsed Peripheral T-Cell Non-Hodgkin's Lymphomas After Reduced-Intensity Conditioning Followed by Allogeneic Transplantation of Hematopoietic Cells. Journal of Clinical Oncology, 2004, 22, 2172-2176.	0.8	301
714	Phosphodiesterase IV Inhibition by Piclamilast Potentiates the Cytodifferentiating Action of Retinoids in Myeloid Leukemia Cells. Journal of Biological Chemistry, 2004, 279, 42026-42040.	1.6	35
715	Incidence of novel N-glycosylation sites in the B-cell receptor of lymphomas associated with immunodeficiency. British Journal of Haematology, 2004, 124, 604-609.	1.2	7
716	Aberrant somatic hypermutation in post-transplant lymphoproliferative disorders. British Journal of Haematology, 2004, 127, 322-325.	1.2	25
717	Development of a quantitative-PCR method for specific FLT3/ITD monitoring in acute myeloid leukemia. Leukemia, 2004, 18, 1441-1444.	3.3	23
718	Suicide gene therapy and the control of graft-vs-host disease. Best Practice and Research in Clinical Haematology, 2004, 17, 453-463.	0.7	3
719	Reduced-Intensity Conditioning (RIC) Followed by Allogeneic Transplantation in Relapsed Lymphomas: Evidence for Graft-Versus-Lymphoma Effect in Low and High Grade Histologies, but Not in Hodgkin Disease.. Blood, 2004, 104, 808-808.	0.6	5
720	Long-Term Follow-Up of High-Dose Chemotherapy Followed by Autologous Stem Cell Transplantation in Peripheral T-Cell Lymphomas at Diagnosis.. Blood, 2004, 104, 909-909.	0.6	2

#	ARTICLE	IF	CITATIONS
721	Treatment of Severe Aplastic Anaemia (SAA) with Antilymphocyte Globulin (ALG), Cyclosporine (CyA) and Granulocyte Colony Stimulating Factor (G-CSF) 5 1¼G vs 10 1¼G/Kg : A Gitmo Prospective Randomized Study.. Blood, 2004, 104, 3700-3700.	0.6	0
722	Molecular Remission Can Be Attained in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Follicular Lymphomas after Reduced Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (ALLO-SCT).. Blood, 2004, 104, 2317-2317.	0.6	0
723	Reduced-Intensity Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in Patients Older Than 60 Years.. Blood, 2004, 104, 5134-5134.	0.6	0
724	A Predictive Model for Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL): A Retrospective Analysis of 1,252 Cases Performed by the Intergruppo Italiano Linfomi (IIL).. Blood, 2004, 104, 3261-3261.	0.6	0
725	Treatment of severe aplastic anemia with antilymphocyte globulin, cyclosporine and two different granulocyte colony-stimulating factor regimens: a GITMO prospective randomized study. Haematologica, 2004, 89, 1054-61.	1.7	22
726	Innovative cell-based therapies in onco-hematology: what are the clinical facts ?. Haematologica, 2004, 89, 1253-60.	1.7	9
727	Effect of alemtuzumab on neoplastic B cells. Haematologica, 2004, 89, 1476-83.	1.7	72
728	Gene expression profile unravels significant differences between childhood and adult Ph+ acute lymphoblastic leukemia. Leukemia, 2003, 17, 2234-2237.	3.3	16
729	The course of monoclonal "villous" lymphocytosis over 15 years of follow-up: progression to SLVL or spontaneous clinical but not molecular remission. Leukemia, 2003, 17, 2243-2244.	3.3	2
730	Anabolic-androgenic steroids for alcoholic liver disease. , 2003, , CD003045.		11
731	Differential response of human acute myeloid leukemia cells to gemtuzumab ozogamicin in vitro: role of Chk1 and Chk2 phosphorylation and caspase 3. Blood, 2003, 101, 4589-4597.	0.6	76
732	Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood, 2003, 102, 749-755.	0.6	193
733	Molecular histogenesis of posttransplantation lymphoproliferative disorders. Blood, 2003, 102, 3775-3785.	0.6	108
734	Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2. Haematologica, 2003, 88, 1002-12.	1.7	90
735	Lymphomas occurring late after solid-organ transplantation. Transplantation, 2002, 74, 1095-1102.	0.5	129
736	Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. Blood, 2002, 99, 75-82.	0.6	147
737	Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood, 2002, 99, 856-862.	0.6	155
738	Bis-indols: a novel class of molecules enhancing the cytodifferentiating properties of retinoids in myeloid leukemia cells. Blood, 2002, 100, 3719-3730.	0.6	30

#	ARTICLE	IF	CITATIONS
739	Anabolic-androgenic steroids for alcoholic liver disease: a Cochrane Review. <i>American Journal of Gastroenterology</i> , 2002, 97, 1674-1681.	0.2	12
740	A Human Immunodeficiency Virus Type 1 polGene-Derived Sequence (cPPT/CTS) Increases the Efficiency of Transduction of Human Nondividing Monocytes and T Lymphocytes by Lentiviral Vectors. <i>Human Gene Therapy</i> , 2002, 13, 1793-1807.	1.4	56
741	Negative selection of peripheral blood stem cells to support a tandem autologous transplantation programme in multiple myeloma. <i>British Journal of Haematology</i> , 2002, 116, 202-210.	1.2	40
742	Molecular characterization of a new recombination of the SIL/TAL-1 locus in a child with T-cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2002, 118, 1011-1018.	1.2	14
743	Prolonged administration of all-trans retinoic acid in combination with intensive chemotherapy and G-CSF for adult acute myelogenous leukemia: single-centre pilot study in different risk groups. <i>The Hematology Journal</i> , 2002, 3, 193-200.	2.0	10
744	Phase I trial with escalating doses of idarubicin and multidrug resistance reversal by short-course cyclosporin A, sequential high-dose cytosine arabinoside, and granulocyte colony-stimulating factor for adult patients with refractory acute leukemia. <i>Haematologica</i> , 2002, 87, 257-63.	1.7	7
745	S-adenosyl-L-methionine for alcoholic liver diseases. , 2001, , CD002235.		19
746	Tyrosine kinase inhibitor STI571 potentiates the pharmacologic activity of retinoic acid in acute promyelocytic leukemia cells: effects on the degradation of RAR α and PML-RAR α . <i>Blood</i> , 2001, 97, 3234-3243.	0.6	61
747	CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. <i>Blood</i> , 2001, 98, 3383-3389.	0.6	395
748	Propylthiouracil for alcoholic liver disease. , 2001, , CD002800.		9
749	Colchicine for alcoholic and non-alcoholic liver fibrosis and cirrhosis. , 2001, , CD002148.		18
750	Intensification of salvage treatment with high-dose sequential chemotherapy improves the outcome of patients with refractory or relapsed aggressive non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 2001, 114, 333-341.	1.2	34
751	Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. <i>British Journal of Haematology</i> , 2001, 114, 800-809.	1.2	175
752	Colchicine for alcoholic and non-alcoholic liver fibrosis or cirrhosis. <i>Liver</i> , 2001, 21, 129-136.	0.1	38
753	Meta-analysis of propylthiouracil for alcoholic liver disease - a Cochrane Hepato-Biliary Group Review. <i>Liver</i> , 2001, 21, 398-404.	0.1	36
754	Purified autologous grafting in childhood acute lymphoblastic leukemia in second remission: evidence for long-term clinical and molecular remissions. <i>Leukemia</i> , 2001, 15, 50-56.	3.3	25
755	Risk-oriented postremission strategies in adult acute lymphoblastic leukemia: prospective confirmation of anthracycline activity in standard-risk class and role of hematopoietic stem cell transplants in high-risk groups. <i>The Hematology Journal</i> , 2001, 2, 117-126.	2.0	30
756	Prognostic Factors in Philadelphia+/BCR-ABL+ Acute Lymphoblastic Leukemia. <i>Hamatologie Und Bluttransfusion</i> , 2001, , 426-431.	0.0	0

#	ARTICLE	IF	CITATIONS
757	Pharmacokinetic study of the new cyclosporine-A formulation (Neoral) in adult allogeneic bone marrow transplant recipients. <i>Haematologica</i> , 2001, 86, 311-5.	1.7	7
758	Anti-CD20 antibody (rituximab) administration in patients with late occurring lymphomas after solid organ transplant. <i>Haematologica</i> , 2001, 86, 618-23.	1.7	30
759	Risk-oriented postremission strategies in adult acute lymphoblastic leukemia: prospective confirmation of anthracycline activity in standard-risk class and role of hematopoietic stem cell transplants in high-risk groups. <i>The Hematology Journal</i> , 2001, 2, 117-26.	2.0	11
760	Colchicine for alcoholic and non-alcoholic liver fibrosis and cirrhosis. <i>Liver</i> , 2000, 20, 262-266.	0.1	2
761	Retinoid-dependent growth inhibition, differentiation and apoptosis in acute promyelocytic leukemia cells. Expression and activation of caspases. <i>Cell Death and Differentiation</i> , 2000, 7, 447-460.	5.0	84
762	Molecular profile of Epstein-Barr virus infection in HHV-8-positive primary effusion lymphoma. <i>Leukemia</i> , 2000, 14, 271-277.	3.3	60
763	Mild hypothermia delays the onset of coma and prevents brain edema and extracellular brain glutamate accumulation in rats with acute liver failure. <i>Hepatology</i> , 2000, 31, 872-877.	3.6	116
764	Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. <i>Blood</i> , 2000, 95, 3900-3908.	0.6	523
765	Isolation and characterization of an acute promyelocytic leukemia cell line selectively resistant to the novel antileukemic and apoptogenic retinoid 6-[3-adamantyl-4-hydroxyphenyl]-2-naphthalene carboxylic acid. <i>Blood</i> , 2000, 95, 2672-2682.	0.6	39
766	Beneficial effect of hypothermia in acute liver failure: Delayed onset of brain edema and alterations of brain amino acid profiles. <i>Journal of Hepatology</i> , 2000, 32, 49.	1.8	0
767	Genetic Modification of Human T Cells with CD20: A Strategy to Purify and Lyse Transduced Cells with Anti-CD20 Antibodies. <i>Human Gene Therapy</i> , 2000, 11, 611-620.	1.4	126
768	Role of early anthracycline dose-intensity according to expression of Philadelphia chromosome/BCR-ABL rearrangements in B-precursor adult acute lymphoblastic leukemia. <i>The Hematology Journal</i> , 2000, 1, 226-234.	2.0	16
769	EPSTEIN-BARR VIRUS-NEGATIVE LYMPHOPROLIFERATIVE DISORDERS IN LONG-TERM SURVIVORS AFTER HEART, KIDNEY, AND LIVER TRANSPLANT1. <i>Transplantation</i> , 2000, 69, 827-833.	0.5	144
770	Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. <i>Blood</i> , 2000, 95, 3900-3908.	0.6	124
771	Isolation and characterization of an acute promyelocytic leukemia cell line selectively resistant to the novel antileukemic and apoptogenic retinoid 6-[3-adamantyl-4-hydroxyphenyl]-2-naphthalene carboxylic acid. <i>Blood</i> , 2000, 95, 2672-2682.	0.6	5
772	Possible Prognostic Benefit from ABMT in First Remission Adult Acute Lymphoblastic Leukemia. , 2000, , 217-225.		0
773	Isolation and characterization of an acute promyelocytic leukemia cell line selectively resistant to the novel antileukemic and apoptogenic retinoid 6-[3-adamantyl-4-hydroxyphenyl]-2-naphthalene carboxylic acid. <i>Blood</i> , 2000, 95, 2672-82.	0.6	11
774	Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. <i>Blood</i> , 2000, 95, 3900-8.	0.6	173

#	ARTICLE	IF	CITATIONS
775	Need for an accurate molecular diagnosis to assess the donor origin of leukemia relapse after allogeneic stem cell transplantation. <i>Haematologica</i> , 2000, 85, 1153-7.	1.7	19
776	Clinical outcome after autologous transplantation in non-Hodgkin's lymphoma patients with high international prognostic index (IPI). <i>Annals of Oncology</i> , 1999, 10, 427-432.	0.6	16
777	The Novel Synthetic Retinoid 6-[3-adamantyl-4-hydroxyphenyl]-2-naphthalene Carboxylic Acid (CD437) Causes Apoptosis in Acute Promyelocytic Leukemia Cells Through Rapid Activation of Caspases. <i>Blood</i> , 1999, 93, 1045-1061.	0.6	79
778	The effects of the level of ampicillin resistance and the inoculum size on the in-vitro bactericidal activity of the combination of ampicillin and ciprofloxacin against high-level gentamicin-resistant strains of <i>Enterococcus faecium</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 1999, 44, 719-720.	1.3	0
779	Induction-consolidation with an idarubicin-containing regimen, unpurged marrow autograft, and post-graft chemotherapy in adult acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 1999, 104, 755-762.	1.2	20
780	Leucocyte alkaline phosphatase identifies terminally differentiated normal neutrophils and its lack in chronic myelogenous leukaemia is not dependent on p210 tyrosine kinase activity. <i>British Journal of Haematology</i> , 1999, 105, 163-172.	1.2	16
781	Primary effusion lymphoma after heart transplantation: a new entity associated with human herpesvirus-8. <i>Leukemia</i> , 1999, 13, 664-670.	3.3	116
782	Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. <i>Leukemia</i> , 1999, 13, 1901-1928.	3.3	1,038
783	Characterization of the human myeloid leukemia-derived cell line GF-D8 by multiplex fluorescence in situ hybridization, subtelomeric probes, and comparative genomic hybridization. <i>Genes Chromosomes and Cancer</i> , 1999, 24, 213-221.		34
784	Clinical Sensitivity to Anthracyclines in PH/BCR+ Acute Lymphoblastic Leukemia. <i>Advances in Experimental Medicine and Biology</i> , 1999, 457, 489-499.	0.8	4
785	The Novel Synthetic Retinoid 6-[3-adamantyl-4-hydroxyphenyl]-2-naphthalene Carboxylic Acid (CD437) Causes Apoptosis in Acute Promyelocytic Leukemia Cells Through Rapid Activation of Caspases. <i>Blood</i> , 1999, 93, 1045-1061.	0.6	11
786	The novel synthetic retinoid 6-[3-adamantyl-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) causes apoptosis in acute promyelocytic leukemia cells through rapid activation of caspases. <i>Blood</i> , 1999, 93, 1045-61.	0.6	32
787	Leucocyte alkaline phosphatase identifies terminally differentiated normal neutrophils and its lack in chronic myelogenous leukaemia is not dependent on p210 tyrosine kinase activity. <i>British Journal of Haematology</i> , 1999, 105, 163-72.	1.2	4
788	Characterization of the human myeloid leukemia-derived cell line GF-D8 by multiplex fluorescence in situ hybridization, subtelomeric probes, and comparative genomic hybridization. <i>Genes Chromosomes and Cancer</i> , 1999, 24, 213-21.	1.5	3
789	Infective endocarditis presenting as polyarthritis. <i>Clinical Rheumatology</i> , 1998, 17, 518-520.	1.0	7
790	Rapid retroviral infection of human haemopoietic cells of different lineages: efficient transfer in fresh T cells. <i>British Journal of Haematology</i> , 1998, 103, 449-461.	1.2	22
791	In-vitro activity of combined ampicillin and ciprofloxacin against high-level gentamicin-resistant strains of <i>Enterococcus faecium</i> : influence of the medium on susceptibility test results. <i>Journal of Antimicrobial Chemotherapy</i> , 1998, 41, 139-140.	1.3	3
792	Innovative Two-Step Negative Selection of Granulocyte Colony-Stimulating Factor-Mobilized Circulating Progenitor Cells: Adequacy for Autologous and Allogeneic Transplantation. <i>Blood</i> , 1998, 91, 2189-2196.	0.6	40

#	ARTICLE	IF	CITATIONS
793	Flow Cytometry of Leukocyte Alkaline Phosphatase in Human Hematopoietic Cells. <i>Hamatologie Und Bluttransfusion</i> , 1998, , 62-67.	0.0	0
794	Innovative Two-Step Negative Selection of Granulocyte Colony-Stimulating Factor- Mobilized Circulating Progenitor Cells: Adequacy for Autologous and Allogeneic Transplantation. <i>Blood</i> , 1998, 91, 2189-2196.	0.6	0
795	Innovative two-step negative selection of granulocyte colony-stimulating factor-mobilized circulating progenitor cells: adequacy for autologous and allogeneic transplantation. <i>Blood</i> , 1998, 91, 2189-96.	0.6	2
796	A new combination of carboplatin, high-dose cytarabine and cross-over mitoxantrone or idarubicin for refractory and relapsed acute myeloid leukemia. <i>Haematologica</i> , 1998, 83, 422-7.	1.7	9
797	The Role of Idarubicin in Adult Acute Lymphoblastic Leukaemia: From Drug Resistance Studies to Clinical Application. <i>Leukemia and Lymphoma</i> , 1997, 26, 89-97.	0.6	18
798	Combination of co-trimoxazole and ciprofloxacin as therapy of a patient with infective endocarditis caused by an enterococcus highly resistant to gentamicin. <i>Journal of Antimicrobial Chemotherapy</i> , 1997, 40, 737-738.	1.3	10
799	Granulocyte colony-Stimulating factor (G-CSF, filgrastim) after or during an intensive remission induction therapy for adult acute lymphoblastic leukaemia: Effects, role of patient pretreatment characteristics, and costs. <i>Leukemia and Lymphoma</i> , 1997, 26, 153-161.	0.6	26
800	Identification of Two Novel Isoforms of the ZNF162 Gene: A Growing Family of Signal Transduction and Activator of RNA Proteins. <i>Genomics</i> , 1997, 42, 268-277.	1.3	11
801	Stat1 Is Induced and Activated by All-Trans Retinoic Acid in Acute Promyelocytic Leukemia Cells. <i>Blood</i> , 1997, 89, 1001-1012.	0.6	111
802	A human acute lymphoblastic leukemia line with the T(4;11) translocation as a model of minimal residual disease in SCID mice. <i>Leukemia Research</i> , 1997, 21, 1107-1114.	0.4	18
803	BEAM chemotherapy and autologous haemopoietic progenitor cell transplantation as front-line therapy for high-risk patients with diffuse large cell lymphoma. <i>British Journal of Haematology</i> , 1997, 99, 379-385.	1.2	24
804	Long-term haematological reconstitution following BEAM and autologous transplantation of circulating progenitor cells in non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 1997, 96, 620-626.	1.2	8
805	Flow cytometry of leucocyte alkaline phosphatase in normal and pathologic leucocytes. <i>British Journal of Haematology</i> , 1997, 96, 815-822.	1.2	15
806	Effect of alltrans-retinoic acid (ATRA) on the adhesive and motility properties of acute promyelocytic leukemia cells. , 1997, 70, 72-77.		21
807	Stat1 is induced and activated by all-trans retinoic acid in acute promyelocytic leukemia cells. <i>Blood</i> , 1997, 89, 1001-12.	0.6	37
808	Mobilization and collection of PBSC in healthy donors: a retrospective analysis of the Italian Bone Marrow Transplantation Group (GITMO). <i>Haematologica</i> , 1997, 82, 47-52.	1.7	29
809	The Natural History of Monoclonal Villous Lymphocytosis: A Chronic Lymphoproliferative Disorder of CD11c+ B Cells. <i>Leukemia and Lymphoma</i> , 1996, 21, 181-183.	0.6	3
810	Molecular Diagnosis and Clinical Relevance of t(9;22), t(4;11) and t(1;19) Chromosome Abnormalities in a Consecutive Group of 141 Adult Patients with Acute Lymphoblastic Leukemia. <i>Leukemia and Lymphoma</i> , 1996, 21, 457-466.	0.6	28

#	ARTICLE	IF	CITATIONS
811	Effects of 1,25-Dihydroxy Vitamin D3 on All-Trans Retinoic Acid Sensitive and Resistant Acute Promyelocytic Leukemia Cells. <i>Biochemical and Biophysical Research Communications</i> , 1996, 224, 50-56.	1.0	20
812	AM580, a stable benzoic derivative of retinoic acid, has powerful and selective cyto-differentiating effects on acute promyelocytic leukemia cells. <i>Blood</i> , 1996, 87, 1520-1531.	0.6	69
813	PREVALENCE OF ALCOHOL PROBLEMS IN GENERAL PRACTICE: AN EXPERIENCE FROM SOUTHERN ITALY. <i>Alcohol and Alcoholism</i> , 1996, 31, 191-196.	0.9	4
814	Detection of the breakpoint cluster region-ABL fusion in chronic myeloid leukemia with variant Philadelphia chromosome translocations by in situ hybridization. <i>Cancer Genetics and Cytogenetics</i> , 1996, 89, 153-156.	1.0	5
815	Molecular diagnosis and monitoring of acute myeloid leukemia. <i>Leukemia Research</i> , 1996, 20, 801-807.	0.4	19
816	Interferons induce normal and aberrant retinoic-acid receptors type β in acute promyelocytic leukemia cells: Potentiation of the induction of retinoid-dependent differentiation markers. , 1996, 68, 75-83.		22
817	Role of Anthracyclines in the Treatment of Adult Acute Lymphoblastic Leukemia. <i>Acta Haematologica</i> , 1996, 95, 188-192.	0.7	4
818	Age-Adapted Moderate-Dose Induction and Flexible Outpatient Postremission Therapy for Elderly Patients with Acute Lymphoblastic Leukemia. <i>Leukemia and Lymphoma</i> , 1996, 22, 295-301.	0.6	39
819	Unorthodox antibiotic combinations including ciprofloxacin against high-level gentamicin resistant enterococci. <i>Journal of Antimicrobial Chemotherapy</i> , 1996, 37, 727-736.	1.3	21
820	The Role of Anthracycline S in the Management of Adult Acute Lymphoblastic Leukaemia. , 1996, , 215-219.		0
821	AM580, a stable benzoic derivative of retinoic acid, has powerful and selective cyto-differentiating effects on acute promyelocytic leukemia cells. <i>Blood</i> , 1996, 87, 1520-31.	0.6	25
822	Expression of A-myb, but not c-myb and B-myb, is restricted to Burkitt's lymphoma, slg+ B-acute lymphoblastic leukemia, and a subset of chronic lymphocytic leukemias. <i>Blood</i> , 1996, 87, 1900-11.	0.6	20
823	G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation of resistant or relapsing acute leukemias. <i>Leukemia</i> , 1996, 10, 860-5.	3.3	11
824	Therapeutic impact of adult-type acute lymphoblastic leukemia regimens in B-cell/L3 acute leukemia and advanced-stage Burkitt's lymphoma. <i>Haematologica</i> , 1996, 81, 442-9.	1.7	8
825	Identification of chromosomal rearrangements in the human myeloid leukemia cell line GF-D8 by dual-colour fluorescence in situ hybridization. <i>Hematological Oncology</i> , 1995, 13, 177-183.	0.8	0
826	Establishment of human acute myelogenous leukemia lines secreting interleukin- 1β in SCID mice. <i>International Journal of Cancer</i> , 1995, 61, 280-285.	2.3	14
827	Adult polyomyositis/dermatomyositis associated with acute myeloid leukemia. A case report. <i>Clinical Rheumatology</i> , 1995, 14, 217-219.	1.0	7
828	Visceral leishmaniasis during pregnancy treated with meglumine antimoniate. <i>Infection</i> , 1995, 23, 182-183.	2.3	21

#	ARTICLE	IF	CITATIONS
829	All-trans retinoic acid and cyclic adenosine monophosphate cooperate in the expression of leukocyte alkaline phosphatase in acute promyelocytic leukemia cells. <i>Blood</i> , 1995, 85, 3619-3635.	0.6	50
830	Constitutive expression of GATA-1, EPOR, alpha-globin, and gamma-globin genes in myeloid clonogenic cells from juvenile chronic myelocytic leukemia. <i>Blood</i> , 1995, 86, 323-328.	0.6	17
831	Granulocyte colony-stimulating factor following peripheral-blood progenitor-cell transplant in non-Hodgkin's lymphoma.. <i>Journal of Clinical Oncology</i> , 1995, 13, 935-941.	0.8	50
832	Tyrosine Kinases but Not cAMP-Dependent Protein Kinase Mediate the Induction of Leukocyte Alkaline Phosphatase by Granulocyte-Colony-Stimulating Factor and Retinoic Acid in Acute Promyelocytic Leukemia Cells. <i>Biochemical and Biophysical Research Communications</i> , 1995, 208, 846-854.	1.0	14
833	Autologous PBSC transplant for late onset AML after mafosfamide-purged and TBI-containing autologous BMT. <i>Bone Marrow Transplantation</i> , 1995, 15, 791-3.	1.3	1
834	The use of anthracyclines in adult acute lymphoblastic leukemia. <i>Haematologica</i> , 1995, 80, 280-91.	1.7	10
835	All-trans retinoic acid and cyclic adenosine monophosphate cooperate in the expression of leukocyte alkaline phosphatase in acute promyelocytic leukemia cells. <i>Blood</i> , 1995, 85, 3619-35.	0.6	11
836	Short-term treatment for adult hypergranular and microgranular acute promyelocytic leukemia. <i>Leukemia</i> , 1995, 9, 238-43.	3.3	21
837	Human monocytic leukemia expresses low levels of asparagine synthase and is potentially sensitive to L-asparaginase. <i>Leukemia</i> , 1995, 9, 360-1.	3.3	13
838	Prevalence of alcohol problems among adult somatic in-patients in Naples. <i>Alcohol and Alcoholism</i> , 1995, 30, 441-8.	0.9	4
839	Effects of dexamethasone on pro-inflammatory cytokine expression, cell growth and maturation during granulocytic differentiation of acute promyelocytic leukemia cells. <i>European Cytokine Network</i> , 1995, 6, 157-65.	1.1	18
840	Dissociation between p93B-myb and p75c-myb expression during the proliferation and differentiation of human myeloid cell lines. <i>Blood</i> , 1994, 83, 1778-1790.	0.6	23
841	Retinoic acid and granulocyte colony-stimulating factor synergistically induce leukocyte alkaline phosphatase in acute promyelocytic leukemia cells. <i>Blood</i> , 1994, 83, 1909-1921.	0.6	72
842	Interferon Alfa-2a as Compared with Conventional Chemotherapy for the Treatment of Chronic Myeloid Leukemia. <i>New England Journal of Medicine</i> , 1994, 330, 820-825.	13.9	565
843	Determination of orally administered all-trans-retinoic acid in human plasma by high-performance liquid chromatography. <i>Biomedical Applications</i> , 1994, 656, 239-244.	1.7	18
844	Polymerase chain reaction (PCR) approach for the evaluation of minimal residual disease in acute leukemia. <i>Stem Cells</i> , 1994, 12, 394-401.	1.4	12
845	Unexpected remission of acute myeloid leukaemia after GM-CSF. <i>British Journal of Haematology</i> , 1994, 87, 835-838.	1.2	15
846	Dissociation between p93B-myb and p75c-myb expression during the proliferation and differentiation of human myeloid cell lines. <i>Blood</i> , 1994, 83, 1778-1790.	0.6	3

#	ARTICLE	IF	CITATIONS
847	Polymerase Chain Reaction Approach for the Evaluation of Minimal Residual Disease in Acute Leukemia. <i>Hamatologie Und Bluttransfusion</i> , 1994, , 9-14.	0.0	0
848	Retinoic acid and granulocyte colony-stimulating factor synergistically induce leukocyte alkaline phosphatase in acute promyelocytic leukemia cells. <i>Blood</i> , 1994, 83, 1909-21.	0.6	14
849	Expression of GATA-1 mRNA in human myeloid leukemic cells. <i>Leukemia</i> , 1994, 8, 1034-8.	3.3	11
850	Cancer procoagulant in the human promyelocytic cell line NB4 and its modulation by all-trans-retinoic acid. <i>Leukemia</i> , 1994, 8, 156-9.	3.3	35
851	Reinforced HEAV'D therapy for adult acute lymphoblastic leukemia: Improved results and revised prognostic criteria. <i>Hematological Oncology</i> , 1993, 11, 169-177.	0.8	9
852	Transcriptional and post-transcriptional regulation of IL-1, IL-6 and TNF- α genes in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 1993, 83, 204-211.	1.2	19
853	Idarubicin in the Initial Treatment of Adults with Acute Lymphoblastic Leukemia: The Effect of Drug Schedule on Outcome. <i>Leukemia and Lymphoma</i> , 1993, 11, 105-110.	0.6	26
854	Clinical and Biological Effects of Erythropoietin treatment of Myelodysplastic Syndrome. <i>Leukemia and Lymphoma</i> , 1993, 10, 127-134.	0.6	4
855	Establishment and characterization of a new granulocyte-macrophage colony-stimulating factor-dependent and interleukin-3-dependent human acute myeloid leukemia cell line (GF-D8). <i>Blood</i> , 1993, 81, 1376-1383.	0.6	28
856	Detection of ALL-1/AF4 fusion transcript by reverse transcription- polymerase chain reaction for diagnosis and monitoring of acute leukemias with the t(4;11) translocation. <i>Blood</i> , 1993, 82, 2943-2947.	0.6	100
857	Interleukin-1 and Glomerular Mesangial Cells. <i>Kidney and Blood Pressure Research</i> , 1993, 16, 89-92.	0.9	3
858	Molecular Genetics of the t(15;17) Translocation in Acute Promyelocytic Leukemia. <i>Recent Results in Cancer Research</i> , 1993, 131, 345-359.	1.8	0
859	Intensive therapy for adult acute lymphoblastic leukemia: preliminary results of the idarubicin/vincristine/L-asparaginase/prednisolone regimen. <i>Seminars in Oncology</i> , 1993, 20, 39-46.	0.8	13
860	Procoagulant Cell Activities in Acute Leukemia. <i>Leukemia and Lymphoma</i> , 1992, 7, 49-51.	0.6	1
861	Neurological symptoms and coma associated with doxorubicin administration during chronic cyclosporin therapy. <i>Lancet, The</i> , 1992, 339, 1421.	6.3	30
862	25. Expression of the erythroid-specific transcription factor GATA-1 in human myeloid leukenic cells. <i>Biomedicine and Pharmacotherapy</i> , 1992, 46, 250.	2.5	0
863	Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukaemia. <i>Lancet, The</i> , 1992, 340, 1437-1438.	6.3	214
864	Genomic variability and alternative splicing generate multiple PML/RAR alpha transcripts that encode aberrant PML proteins and PML/RAR alpha isoforms in acute promyelocytic leukaemia.. <i>EMBO Journal</i> , 1992, 11, 1397-1407.	3.5	245

#	ARTICLE	IF	CITATIONS
865	Molecular monitoring of the myl/retinoic acid receptor-alpha fusion gene in acute promyelocytic leukemia by polymerase chain reaction. <i>Blood</i> , 1992, 80, 492-497.	0.6	154
866	Methylprednisolone dosage effects on peripheral lymphocyte subpopulations and eicosanoid synthesis. <i>Kidney International</i> , 1992, 42, 981-990.	2.6	21
867	THERAPY WITH HUMAN RECOMBINANT ERYTHROPOIETIN IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES. <i>British Journal of Haematology</i> , 1992, 81, 628-630.	1.2	12
868	Constitutive expression of IL-1 β , M-CSF and c-fms during the myeloid blastic phase of chronic myelogenous leukaemia. <i>British Journal of Haematology</i> , 1992, 80, 310-316.	1.2	9
869	Intensive retreatment of adults and children with acute lymphoblastic leukemia. <i>Hematological Oncology</i> , 1992, 10, 105-110.	0.8	6
870	Acute undifferentiated leukemia with CD7+ and CD13+ immunophenotype. Lack of molecular lineage commitment and association with poor prognostic features. <i>Cancer</i> , 1992, 69, 396-404.	2.0	32
871	Interleukin-1 regulates cytokine gene expression in human mesangial cells through the interleukin-1 receptor type 1. <i>Journal of the American Society of Nephrology: JASN</i> , 1992, 2, 1709-1715.	3.0	10
872	Genomic variability and alternative splicing generate multiple PML/RAR alpha transcripts that encode aberrant PML proteins and PML/RAR alpha isoforms in acute promyelocytic leukaemia. <i>EMBO Journal</i> , 1992, 11, 1397-407.	3.5	84
873	Soluble intercellular adhesion molecule 1 is released by human melanoma cells and is associated with tumor growth in nude mice. <i>Cancer Research</i> , 1992, 52, 2628-30.	0.4	81
874	Translocation breakpoint of acute promyelocytic leukemia lies within the retinoic acid receptor alpha locus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1991, 88, 1977-1981.	3.3	239
875	RAR-alpha gene rearrangements as a genetic marker for diagnosis and monitoring in acute promyelocytic leukemia. <i>Blood</i> , 1991, 77, 1418-1422.	0.6	103
876	Molecular evaluation of response to all-trans-retinoic acid therapy in patients with acute promyelocytic leukemia. <i>Blood</i> , 1991, 77, 1657-1659.	0.6	80
877	Modulation of cell proliferation and cytokine production in acute myeloblastic leukemia by interleukin-1 receptor antagonist and lack of its expression by leukemic cells. <i>Blood</i> , 1991, 78, 3248-3253.	0.6	128
878	Organ-specific growth of a murine lymphoma of spontaneous origin in nude mice. <i>Clinical and Experimental Metastasis</i> , 1991, 9, 485-497.	1.7	2
879	Molecular evaluation of response to all-trans-retinoic acid therapy in patients with acute promyelocytic leukemia. <i>Blood</i> , 1991, 77, 1657-1659.	0.6	0
880	Monoclonal lymphocytosis with villous lymphocytes: a chronic lymphoproliferative disease of CD11c+ B-cells. <i>Leukemia</i> , 1991, 5, 799-806.	3.3	8
881	Modulation of cell proliferation and cytokine production in acute myeloblastic leukemia by interleukin-1 receptor antagonist and lack of its expression by leukemic cells. <i>Blood</i> , 1991, 78, 3248-53.	0.6	30
882	Association of NK-Cell Lymphoproliferative Disease and Nephrotic Syndrome. <i>American Journal of Clinical Pathology</i> , 1990, 94, 334-338.	0.4	17

#	ARTICLE	IF	CITATIONS
883	Interleukin-1 and interleukin-2 control granulocyte- and granulocyte-macrophage colony-stimulating factor gene expression and cell proliferation in cultured acute myeloblastic leukemia. <i>International Journal of Cancer</i> , 1990, 46, 902-907.	2.3	17
884	Rearrangements and aberrant expression of the retinoic acid receptor alpha gene in acute promyelocytic leukemias.. <i>Journal of Experimental Medicine</i> , 1990, 172, 1571-1575.	4.2	202
885	Structure of the gene encoding the human leukocyte adhesion molecule-1 (TQ1, Leu-8) of lymphocytes and neutrophils.. <i>Journal of Biological Chemistry</i> , 1990, 265, 7760-7767.	1.6	87
886	Expression of leukocyte alkaline phosphatase gene in normal and leukemic cells: regulation of the transcript by granulocyte colony- stimulating factor. <i>Blood</i> , 1990, 76, 2565-2571.	0.6	47
887	Structure of the gene encoding the human leukocyte adhesion molecule-1 (TQ1, Leu-8) of lymphocytes and neutrophils. <i>Journal of Biological Chemistry</i> , 1990, 265, 7760-7.	1.6	72
888	A paracrine circuit in the regulation of the proliferation of macrophages infiltrating murine sarcomas. <i>Journal of Immunology</i> , 1990, 144, 2409-12.	0.4	40
889	Expression of c-jun protooncogene in human myelomonocytic cells. <i>Blood</i> , 1989, 74, 1811-1816.	0.6	49
890	Constitutive expression of the interleukin-6 gene in chronic lymphocytic leukemia. <i>Blood</i> , 1989, 73, 1279-1284.	0.6	115
891	Differences in the expression of alkaline phosphatase mRNA in chronic myelogenous leukemia and paroxysmal nocturnal hemoglobinuria polymorphonuclear leukocytes. <i>Blood</i> , 1989, 73, 1113-1115.	0.6	38
892	Recombinant human interleukin 5 is a selective eosinophil chemoattractant. <i>European Journal of Immunology</i> , 1989, 19, 701-705.	1.6	315
893	Autoimmunity and b-cell dysfunction in chronic proliferative disorders of large granular lymphocytes/natural killer cells. <i>Cancer</i> , 1989, 63, 90-95.	2.0	62
894	Functional consequences of monocyte IL-2 receptor expression. Induction of IL-1 beta secretion by IFN gamma and IL-2. <i>Journal of Immunology</i> , 1989, 142, 139-43.	0.4	48
895	Integrated use of morphology, cytochemistry, and immune marker analysis to identify acute leukaemia subtypes. <i>Haematologica</i> , 1989, 74, 487-90.	1.7	10
896	T cell receptor delta gene organization and expression in normal and leukemic natural killer cells. <i>Journal of Immunology</i> , 1989, 143, 1009-14.	0.4	13
897	Association of large granular lymphocyte/natural killer cell proliferative disease and second hematologic malignancy. <i>American Journal of Hematology</i> , 1988, 29, 85-93.	2.0	21
898	Investigation of Chronic Lymphocytosis in Adults. <i>American Journal of Clinical Pathology</i> , 1988, 89, 783-787.	0.4	8
899	Human granulocyte-monocyte colony-stimulating factor and interleukin 3 stimulate monocyte cytotoxicity through a tumor necrosis factor- dependent mechanism. <i>Blood</i> , 1988, 71, 672-676.	0.6	207
900	Independent regulation of M-CSF and G-CSF gene expression in human monocytes. <i>Blood</i> , 1988, 71, 1529-1532.	0.6	191

#	ARTICLE	IF	CITATIONS
901	Expression of the macrophage colony-stimulating factor and c-fms genes in human acute myeloblastic leukemia cells.. Journal of Clinical Investigation, 1988, 81, 1030-1035.	3.9	119
902	Induction of monocyte migration by recombinant macrophage colony-stimulating factor. Journal of Immunology, 1988, 141, 575-9.	0.4	149
903	c-sis but not c-fos gene expression is lineage specific in human myeloid cells. Blood, 1988, 71, 488-493.	0.6	1
904	Human granulocyte-monocyte colony-stimulating factor and interleukin 3 stimulate monocyte cytotoxicity through a tumor necrosis factor- dependent mechanism. Blood, 1988, 71, 672-676.	0.6	9
905	Independent regulation of M-CSF and G-CSF gene expression in human monocytes. Blood, 1988, 71, 1529-1532.	0.6	9
906	Expression of the M-CSF (CSF-1) gene by human monocytes. Blood, 1987, 69, 1409-1413.	0.6	230
907	Secretion of interleukin-1 by acute myeloblastic leukemia cells in vitro induces endothelial cells to secrete colony stimulating factors. Blood, 1987, 70, 1218-1221.	0.6	201
908	T-cell receptor gene rearrangements and expression in normal human large granular lymphocytes (LGL) and their pathological expansions. Cytotechnology, 1987, 1, 79-81.	0.7	0
909	Interferon- β induces expression of the interleukin 2 receptor gene in human monocytes. European Journal of Immunology, 1987, 17, 153-156.	1.6	55
910	Human granulocyte-macrophage colony-stimulating factor induces expression of the tumor necrosis factor gene by the U937 cell line and by normal human monocytes.. Journal of Clinical Investigation, 1987, 79, 1720-1728.	3.9	152
911	Secretion of interleukin-1 by acute myeloblastic leukemia cells in vitro induces endothelial cells to secrete colony stimulating factors. Blood, 1987, 70, 1218-1221.	0.6	4
912	T cell receptor (alpha, beta, gamma) gene rearrangements and expression in normal and leukemic large granular lymphocytes/natural killer cells. Blood, 1987, 70, 1500-8.	0.6	47
913	Expression of the M-CSF (CSF-1) gene by human monocytes. Blood, 1987, 69, 1409-13.	0.6	39
914	Induction of cytotoxicity by interleukin-2 in T^3 -lymphoproliferative disorders. International Journal of Cancer, 1986, 37, 27-33.	2.3	15
915	Lymphokine Production in Ty Lymphoproliferative Disorders. Scandinavian Journal of Immunology, 1986, 23, 183-188.	1.3	13
916	Large granular lymphocyte/natural killer cell proliferative disease: Clinical and laboratory heterogeneity. Scandinavian Journal of Haematology, 1986, 37, 91-96.	0.0	17
917	Immunological and genotypic analysis of human T^3 -lymphoproliferative disorders. Research in Clinic and Laboratory, 1986, 16, 29-35.	0.3	3
918	Migratory capacity of large granular lymphocytes from T-gamma-lymphoproliferative disorders. Natural Immunity and Cell Growth Regulation, 1986, 5, 19-27.	0.2	0

#	ARTICLE	IF	CITATIONS
919	Induction of monocyte-macrophage procoagulant activity by transformed cell lines. Journal of Immunology, 1986, 136, 3848-55.	0.4	17
920	Production of Interleukin 1 but not of Procoagulant Activity by Large Granular Lymphocytes. Scandinavian Journal of Immunology, 1985, 22, 363-366.	1.3	3
921	Intraperitoneal administration of interferon \hat{I}^2 in ovarian cancer patients. Cancer, 1985, 56, 294-301.	2.0	61
922	T cell receptor beta chain gene rearrangements in lymphoproliferative disorders of large granular lymphocytes/natural killer cells.. Journal of Experimental Medicine, 1985, 162, 2156-2162.	4.2	116
923	Study of the production of a strange ($S = \hat{a}^1$) dibaryon in the interactions of $K\hat{a}^{\sim}$ and $\hat{I}^{\epsilon+}$ on deuterium below 1.5GeV/c. Nuclear Physics B, 1985, 249, 172-188.	0.9	38
924	Human mononuclear phagocytes from different anatomical sites differ in their capacity to metabolize arachidonic acid. Clinical and Experimental Immunology, 1984, 57, 385-92.	1.1	16
925	Effect of a streptococcal preparation (OK432) on natural killer activity of tumour-associated lymphoid cells in human ovarian carcinoma and on lysis of fresh ovarian tumour cells. British Journal of Cancer, 1983, 48, 515-525.	2.9	30
926	Search for strange ($S = \hat{a}^2$) dibaryons in the reaction $K\hat{a}^{\sim} + d \hat{a}^{\dagger} K + MM$ at 1.4 GeV/c. Nuclear Physics B, 1982, 209, 1-15.	0.9	15
927	A missing-mass spectrometer for momenta below 1.5 GeV/c. Nuclear Instruments & Methods in Physics Research, 1981, 188, 29-40.	0.9	3
928	High resolution time-of-flight measurements in small and large scintillation counters. Nuclear Instruments & Methods in Physics Research, 1981, 185, 49-65.	0.9	17
929	Study of the missing-mass spectra in the reactions $\hat{I}^{\epsilon^{\sim}} d \hat{a}^{\dagger} K + MM$ and $K\hat{a}^{\sim} d \hat{a}^{\dagger} \hat{I}^{\epsilon+} + MM$ at 1.4 GeV/c to search for strange dibaryon states. Physics Letters, Section B: Nuclear, Elementary Particle and High-Energy Physics, 1981, 104, 330-334.	1.5	9
930	Mass spectrum in the Q-Region of strange mesons produced in $\hat{I}^{\epsilon^{\sim}}-p$ Collisions at 6.15 GeV/c. Lettere Al Nuovo Cimento Rivista Internazionale Della SocietA Italiana Di Fisica, 1975, 13, 265-268.	0.4	1